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CHAPTER I 
OUTLINE AND OBJECTIVES OF THIS STUDY 
Acute myeloid leukaemia (AML) is characterized by an accumu­
lation of immature myeloid cells in the bone marrow and by a 
decreased production of mature granulocytes. The aetiology of th 
arrest in maturation of the myeloid cells is unknown. Treatment 
of AML is aimed at an eradication of the immature myeloid cells 
by cytostatic drugs. The choice and dosage schemes of the variou 
chemotherapeutiс agents have, until now, been empirical. Resear 
into drug metabolism and the kinetics of leukaemic cells in rela­
tion to pharmacodynamics is necessary to improve the results of 
cytostatic treatment on a more rational basis. 
Cytosine arabinoside (Ara-C) is the drug of choice in the treat­
ment of AML. In combination with other cytostatic drugs the inci 
dence of complete remission is at most 50 - 60 °L· (table I ) . To e 
plain the high percentage of failures, the fate of Ara-C in indi 
vidual patients has been investigated. 
Ara-C is either phosphorylated intracel1ularly to its triphospha 
(Ara-CTP) or deaminated to uracil arabinoside, a non-суtotoxiс 
metabolite. Only in the form of Ara-CTP is the drug active as an 
inhibitor of cell growth and DNA synthesis. Large variations in 
phosphorylating and deaminating enzymatic activities have been 
нга-L. ine cnrrerences in ine intracellular дга-ьіг content г 
only depend on the deaminating and phosphorylating enzymalio 
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Regime 
Ara-C + thioguanine 
Ara-C + daunorubicine 
Ara-C + daunorubicine 
+ vincristine 
Ara-C + cyclophosphamide 
+ vincristine 
+ prednisone 
Ara-C + vi neri sti ne 
+ adriamycin 
% complete 
remi ssi on 
65 % 
50 % 
55 t 
5 5 t 
75 % 
Reference 
Clarkson (1972) 
Crowther et al.(1973) 
Rosenthal and Maloney 
(1972) 
Whitecar (1972) 
Mathé et al .(1976) 
Table I. 
Incidence of complete remission obtained in acute myeloid 
leukaemia using t-va-C in combination with other cytostatic 
drugs. 
activities, but also on the time period during which a minimal 
effective plasma drug concentration is maintained. In most treat-
ment schemes Ara-C is administered by intravenous bolus injec-
tions. The effective plasma concentration is the resultant of 
the dosage and the elimination rate ot the drug. The plasma elimi-
nation rate of Ara-C has been determined in several studies in 
which half-life values ranging from 3 to 30 minutes were found. 
The most important studies about Ara-C are reviewed in Chanter 2. 
The aim of our study was to investigate the pharmacokinetics of 
Ara-C in relation to the results of remission inducing therany 
in AML patients. For this study a sensitive and reliable assay 
had to be developed since in the therapeutic range very low 
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plasma drug concentrations were expected, especially since the 
half-life of Ara-C is rather short. This method, a bio-assay, is 
described in Chapter 3. With this assay the half-life of Ara-C 
was determined and related to the results of remission inducing 
therapy in fourteen patients (Chapter 4 ) . Since protein binding 
might affect the distribution of Ara-C, the amount of drug 
bound to plasma proteins was also studied (Chapter 5 ) . The finding 
that the half-life of Ara-C was related significantly to the re-
sult of remission inducing therapy,led to the development of a 
predictive test based on the inhibition of tritiated thymidine 
incorporation into leukaemic bone marrow cells after injection 
of Ara-C (Chapter 6 ) . The degree of inhibition reflects the amount 
of Ara-CTP present in the cell. The relation between the inhibi-
tion of tritiated thymidine incorporation, the half-life and the 
intracellular enzymatic activities is discussed (Chapter 7 ) . 
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CHAPTER 2 
BIOCHEMISTRY AND PHARMACOLOGY OF CYTOSINE ARABINOSIDE 
2.1 MODE OF ACTION OF CYTOSINE ARABINOSIDE 
The compound cytosine arabinoside (Ara-C, 1-ß-D-Arabinofura-
nosyl-cytosine) is an analogue of the naturally occurring nucleo-
side cytidine (fig 2.1). The drug is synthesized according to 
principles outlined by Cohen (1966). It is a fairly stable 
constituent that retains 90 % of its potency after storage at 
neutral pH at room temperature for 6 months (Notari et al., 1971). 
Unlike related dérivâtes such as thymine arabinoside and uracil 
arabinoside, which have been isolated from a Caribbean sponge 
(Bergman et al., 1951, 1955), the drug is not known to occur 
naturally. 
NH2 
A) 
OH OH OH 
Cytidine Cytosine Arabinoside 
Fig 2.1 Struoture of Cytidine and Cytosine Arabinoside 
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The biological activity of Ara-C has been studied in bacteria 
by Slechta et al. ( 1 9 6 1 ) . Relatively high Ara-C concentrations 
(> 2 mM) were necessary to inhibit the growth and respiration of 
E.coli. The cytostatic properties of Ara-C were demonstrated by 
its growth inhibiting effect in a variety of transplantable mouse 
tumors including Sarcoma 180, Ehrlich ascites carcinoma. Leukaemia 
L-1210 and Lymphoma L5178y (Evans et al., 1961, 1 9 6 4 ) , giving a 
high incidence of "cures" (Wodinsky et al., 1 9 7 5 ) . In more de-
tailed studies with bacteria and cell cultures it appeared that the 
inhibition of growth was related to the inhibition of DNA synthesis 
(Lark et al., 1964; Silagi, 1 9 6 5 ) . Treatment of pregnant rats with 
Ara-C, followed by administration of labeled thymidine, showed a 
profound inhibition of DNA synthesis in the embryos (Ritter et al., 
1 9 7 1 ) . 
Many studies have been undertaken to elicit the mode of action 
by which the drug inhibits DNA synthesis. These studies are brief-
ly discussed. 
îil-2^_Spme_releyant_data_about structure and synthesis of DNA. 
In order to put the inhibitory action of Ara-C on DNA synthe-
sis in perspective, a short review of DNA synthesis is given. 
Structure of DNA 
The DNA molecule consists of complementary strands of poly-
nucleotides. Each nucleotide is composed of a pyrimidine or purine 
base, a sugar molecule and phosphoric acid. The pyrimidine bases 
are thymine (T) and cytosine (C) and the purine bases are adenine 
(A) and guanine ( G ) . The sugar molecule is deoxyribose. 
The backbone of each strand consists of the sugar molecules linked 
together through phosphate diester bonds. The bases are covalent-
ly linked to the sugars. Between the bases of the two strands hy-
drogen bonds can be formed i.e. adenine with thymine and guanine 
with cytosine. The DNA strands are complementary to each other 
due to this base pairing (fig 2 . 2 ) . 
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Polynucleotide strand oj lite DüA mo iecule. 
Synthesis of DNA 
During DNA synthesis the nucleotides are formed in the cell-
Initially ribose is phosphorylated at carbon atom 5', then the 
bases are attached to the sugar to form the ribonucleoside 5 1-
monophosphates . After further phosphorylation to ribonucleos i de 
5'-diphosphates the ribose molecule is reduced by a ribonucleo-
si de diphosphate reductase to deoxyribose. These reduced diphos-
phates are again phosphorylated to deoxyribonucleoside 5'-tri-
phosphates ( 5 '-tri phosphates). 
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In early studies it has been found that Ara-C is an inhibitor 
of ribonuoleoside diphospate reductase (Chu et al., 1962, 1965). 
DNA synthesis starts with the unwinding of the two strands of 
the DNA molecule. Each strand serves as a template for a newly 
formed polynucleotide strand. The 5'-tri phosphates approach 
their complementary mates on the single parent strands, are 
held in place loosely by base pairing and are then covalently 
linked to the free З'-hydroxyl group of the sugar in the growing 
daughter chain to form the backbone of the DNA molecule. This 
condensation of 5'-tri phosphate is catalyzed by DNA polymerase. 
This enzyme holds the nucleotides, uses the strands of unwound 
parent DNA as templates and guarantees the specificity of the 
insertion of the new nucleotides. Thus at the end of DNA synthe­
sis pairs of two identical DMA molecules exist in the cell, each 
consisting of one parent and one daughter strand. 
Since Ara-C is also phosphorylated to its triphosphate, it has 
been suggested that inhibition of DNA synthesis might occur after 
incorporation of the drug into DNA, resulting in cessation of 
chain growth (Graham et al., 1970a; Momparler, 1972). In later 
reports it has been suggested that the drug inhibits DNA synthe­
sis by inhibiling the enzymatic activity of DNA polymerase 
(Kimball et al., 1968; Momparler, 1972). 
2 · 1 L^i-LlltlibitiOQ.of .the _ri_bonucl_eos ide _dxBhosßhate_reductase 
by_Ara-Ç. 
An essential step in the biosynthesis of deoxycytidi ne tri-
phospate (dCTP), a precursor molecule in the process of DNA synthe-
sis, is the reduction of cytidine diphosphate (CDP) to deoxy-
cytidine diphosphate (dCDP). 
Chu and Fischer (1962) incubated murine L-5178y lymphoblasts with 
labeled uridine. They found that in the presence of Ara-C the 
intracellular level of dCDP was significantly reduced, while the 
level of CDP was not affected. From these data it was assumed that 
the mode of action of Ara-C on DNA synthesis could be due to an 
inhibition of CDP reduction to dCDP by phosphorylated dérivâtes 
of Ara-C. 
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Moore and Cohen (1965) investigated the effect of phosphorylated 
Ara-C on CDP reduction in crude enzyme extracts from Novikoff- and 
Ehrlich ascites tumor cells. They did not find any significant 
inhibition in the reduction of CDP to dCDP, either by diphosphates 
or by triphosphates of Ara-C. 
Skoog and Nordenskjold (1971) measured the intracellular pools of 
deoxyribonucleotι des in mouse embryo cells in the presence of 
Ara-C They found a transient decrease in the dCTP pool and in­
creased levels of d e o x y r i b o s y l a d e m ne triphosphate, deoxyribosyl-
guanine triphosphate and deoxyribosylthymine triphosphate. 
From these studies it is obvious that the inhibition of CDP-reduc-
tase is not a major step in the inhibition of DNA synthesis by 
Ara-C. 
? i i i 4 i _ l D b l b l ^ 9 G . o f _ D N A _ s ^ n t h e s i s _ b y _ c y t o s i n e _ a r a b i n o s i d e incor-
BQr§tion_i.ntg_DNA. 
Ara-C is rapidly phosphorylated to its triphosphate and 
incorporation of the agent into DNA might be expected. Indeed, 
small amounts of radioactivity in the acid insoluble fraction 
(presumably DNA) have been found when various cell lines were 
incubated with tritiated Ara-C (Chu et al., 1965; Silagi, 1 9 6 5 ) . 
In some of these studies it was demonstrated by enzymatic 
degradation of the nucleic acid that the incorporated radioacti­
vity really originated from Ara-C (Chu et al., 1968; Momparler, 
1972). Despite the evidence that Ara-C is incorporated into DNA, 
the problem remains as to how this incorporation relates to 
inhibition of DNA synthesis. 
Graham and Whitmore (1970a) incubated mouse L-cells with labeled 
Ara-C. After specific enzymatic digestion of DNA they found that 
more than 70 % of the radioactivity was released as a 3'-Ara-CMP. 
These data indicate that Ara-C is incorporated into the DNA chain 
between other nucleotides. The incorporated Ara-C may cause al­
terations in the DNA structure leading to a decreased activity of 
DNA polymerase 
32 Momparler (1972) studied the incorporation of ρ Ara-CMP in a 
cell free system using denaturated DNA. His data, obtained after 
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specific enzymatic di gesti on,suggest that Ara-CMP is incorporated 
at the end of a growing DNA chain, causing termination of further 
chai η growth. 
The relation in mouse L-cells between inhibition of DNA syn­
thesis and loss of cell viability in the presence of different 
Ara-C concentrations was studied by Graham et al. (1970b). They 
found that 3.6 χ 10" M Ara-C could inhibit DNA synthesis by more 
than 97 % for nearly 14 hours without significant effect on cell 
viability. Exposure of cells to concentrations of 7.2 χ 10" M 
caused, in addition to inhibition of DNA synthesis, an irreversi­
ble loss of viabi11ty. 
From these results it can be concluded that Ara-C has a cytostatic 
effect at very low concentrations. At these concentrations DNA syn­
thesis is inhibited initially but is restored after some hours 
and the cells multiply again in culture. At higher concentrations 
the drug is cytocidal. 
2.1.5 Inhibition of DNA_f)olymerase_by Ara-C. 
During DNA synthesis the 5 '-tri phosphates aro incorporated 
into the newly formed polynucleotide strand. The incorporation is 
enzymatically controlled by DNA polymerase as described in para­
graph 2.1.2. In crude preparations of DNA polymerase, extracted 
from Ehrlich ascites cells, it was found that the enzyme was in­
hibited by Ara-CTP (Kimball et al., 1968). Similar results were 
found with DNA polymerase extracted from calf thymus (Fürth et 
al., 1968) and human leukaemic cells (Inagaki et al., 1969). 
Graham and Whitmore (1970) reported that in DNA polymerase ex-
tracts from mouse L-cells, Ara-CTP was a competitive inhibitor 
of the enzyme. The affinity of this enzyme for dCTP and Ara-CTP 
is about equal; in all these studies the inhibition of DNA poly-
merase by Ara-CTP could be reversed by dCTP. 
These data indicate that Ara-CTP competes with dCTP for the active 
sites on DNA polymerase. This was confirmed in a cell-free system 
using a synthetic polynucleotide chain consisting of alternating 
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adenine and thymine nucleotides as template. Ara-CTP did not 
produce any detectable inhibition of the incorporation of 
labeled thymidine triphosphate in the polynucleotide strand. 
(Momparler, 1 9 7 2 ) . 
Conci usi on· 
Intracel1ularly, Ara-C is phosphorylated to Ara-CTP. In this 
form the drug is active as an inhibitor of DNA synthesis. Three 
possible mechanisms of action of the drug have been proposed: the 
inhibition of DNA polymerase, the incorporation of Ara-C into DNA 
and the inhibition of π b o n u c l e o s i d e diphosphate reductase. The 
inhibition of DNA polymerase by Ara-CTP is undoubtedly the major 
site of action of the drug. The amount of Ara-C incorporated into 
DNA is very low but is a consistent finding and may be related 
to irreversible damage of the cell. It is generally accepted 
that the inhibition of π b o n u c l eosi de diphosphate reductase is 
not a significant factor in the mode of action of Ara-C. 
2.2 PHARMACOLOGY OF CYTOSINE ARABINOSIDE 
^ i ^ l ^ I n t r o d u c t i g n 
The concentration of a drug in the direct environment of the 
receptors and the affinity for these receptors determine the 
effect produced by the drug. The drug concentration near the re­
ceptors is governed by the drug concentration in the tissue 
and the plasma. After oral or intravenous administration the drug 
is distributed from the plasma over the entire body. The rate 
of exchange of drug between plasma and tissues depends on the 
tissue perfusion, the tissue volume and the partition of the drug 
between plasma and tissues. On the basis of similarities in blood 
flow the various tissues may be grouped together and considered 
as compartments. All compartments are directly or indirectly in 
contact with the blood. The plasma and the highly vascularized 
tissues which rapidly exchange the drug, may be considered as one, 
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so called central compa/>Lmen t. The other tissues may be consid­
ered as one or two peripheral compartments. The drug concentra­
tion in the tissues does not correlate completely with the plas­
ma concentration due to differences in partition and/or binding 
of drug to the various tissue components. 
Shortly after intravenous injection the drug is distributed over 
the plasma and the tissues of the central compartment.The virtual 
volume of distribution of this compartment may be different for 
different drugs and depends on the amount of tissue to which the 
drug has access. The course of the plasma disappearance curve 
after an intravenous bolus injection represents the processes of 
distribution and elimination of the drug. Since the body can be 
considered as a central compartment with one or two peripheral 
compartments, the semi 1oganthmiс plasma concentration curve is 
not a straight line but is bi- or triphasic. 
In acute leukaemia the primary site of disease is the bone marrow, 
which is a highly vascularized tissue and therefore belongs to 
the central compartment. Thus differences in elimination of 
Ara-C in patients may correlate with clinical response. 
ii^Zi.Pharmaçokinetiçs.of.çytgsine^rabinoside. 
The half-life of cytosine arabinoside 
Many pharmacological studies on distribution and metabolism 
of Ara-C have been performed with the tritium labeled drug. In all 
these studies the levels of radioactivity in body fluids were de-
termined followed by chromatographic separation of Ara-C from its 
metabolite Ara-U. The plasma disappearance curve appeared to be 
biphasic with half life values for the second phase varying from 
5 to 30 minutes (Creasey et al., 1966; Finkelstein et al., 1970). 
For pharmacokinetic studies in a large number of patients, bio-
assays have been developed for the determination of Ara-C in 
plasma using sensitive cell lines or micro-organisms. Pitillo and 
Hunt (1967) described a method using an actinobolin resistant 
strain of Streptococcus faecalis. Hanka et al. (1970) modified 
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this assay system and could then measure Ara-C levels as low 
as 0.1 mg/1. 
These assays, however, were not sensitive enough for pharmacokinet-
ic studies in man. Baguley and Falkenhaug (1971) reported a bio-
assay using mammalian cell lines. The test was based on the inhi-
bition of DNA synthesis in suspensions of L-cells or mouse spleen 
cells. Ara-C plasma concentrations as low as 0.04 mg/1 could be 
detected. In a later report the sensitivity of the test was in-
creased using murine tumor cells (L1210). With this test plasma 
half-life values ranging from 3 to 15 minutes were measured. Al-
though the experimental conditions were not stated, the authors 
reported that a poor bone marrow response was found in patients 
with short half-life values (Baguley et al., 1975). 
Elimination of cytosine arabinoside 
Pharmacological studies of Ara-C have shown that the drug 
rapidly disappears from the plasma after intravenous administra-
tion (Creasey et al., 1966; Momparler et al., 1972). In the liver 
the drug is transformed to uracil arabinoside (Ara-U) by the en-
zyme cytidine deaminase (Camiener, 1967). It could be demonstrated, 
using labeled Ara-C,that 86 % - 96 % of the radioactivity re-
covered in the urine was present in the form of Ara-U (Papac et 
al., 1965; Creasey et al., 1966). 
Ho et al.(1971) recovered 80 % of the radioactivity in the urine 
within 24 hours of administration of labeled Ara-C; 8 % was present 
as Ara-C, 72 % as Ara-U. These studies indicate that Ara-C is 
eliminated by deamination and glomerular filtration. 
2.2.3. Intracellular metabolism of cytosine arabinoside 
The plasma disappearance curve of Ara-C after an intravenous 
bolus injection appears to be biphasic which is typical for the 
distribution of a drug in a two compartment open model with elimi-
nation only from the central compartment (Wagner, 1975). The 
first,rather rapid phase mainly represents the distribution of 
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drug over the two compartments while the second phase represents 
the elimination of the drug. The half-life values of the second 
phase range from 5 to 30 minutes, representing a short exposure 
of the cells to the drug (Creasey et al., 1966; Finkelstein et 
al., 1970; Baguley et al., 1971, 1 9 7 5 ) . In various cell lines it 
has been shown that the drug is transported from the extracellu-
lar fluid into the cell by a carrier mediated diffusion process 
which increases the rate of uptake (Kessel et al., 1968; Mulder 
et al., 1 9 7 5 ) . The enzymatic processes in the cell responsible 
for the activation and inactivation of the drug and their rele-
vance for the result of treatment are discussed below. 
Phosphorylation of cytosine arabinoside 
Phosphorylation of Ara-C was found necessary for the inhi-
bition of DNA synthesis and cell growth (Chu et al., 1 9 6 2 ) . In 
drug resistant cell lines of L1210 and 5178y it was found that 
phosphorylation of both deoxycytidi ne and Ara-C was decreased 
by over 90 % compared with the same drug-sensitive cell lines 
(Chu et al., 1965; Schrecker et al., 1 9 6 8 ) . It was concluded that 
phosphorylation of Ara-C was mediated by deoxycytidi ne kinase 
and that the decrease in the activity of this enzyme was respon-
sible for resistance to the drug. 
Deoxycytidi ne Phosphokinase is a naturally occurring enzyme which 
catalyzes the first phosphorylation step to deoxycytidi ne 5'-
monophosphate and cytosine arabinoside 5'-monophosphate respec-
tively. The biochemical properties of this enzyme were first 
studied in crude extracts of calf thymus (Durham et al., 1968; 
Momparler et al., 1 9 6 8 ) . It appeared that this enzyme is rate 
determining in the conversion of Ara-C to Ara-CTP. 
The second phosphorylation step is catalyzed by cytosine mono-
phosphokinase (Sugino et al., 1966; Schrecker, 1970) and the 
third step by non-specific nucleoside diphosphokinase (Nakamura 
et al., 1 9 6 6 ) . In man deoxycytidine kinase has been found in all 
dividing cells with the highest activity in the spleen (Ho et a l . , 
1 9 7 3 ) . 
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In crude extracts of AML bone marrow blast cells (Tattersall et 
al., 1974) and intact AML peripheral and bone marrow blast cells 
(Ho et al., 1973) a wide range of phosphorylating activity has 
been found. In a recently published study the biochemical proper­
ties of partially purified deoxycytidine Phosphokinase from leu-
kaemic blast cells were determined (Coleman et al., 1975). The 
enzyme demonstrates a greater affinity for deoxycytidine than for 
Ara-C. Of particular interest was the relatively weak inhibition 
by Ara-CTP and the strong inhibition by deoxycytidine and deoxy­
cytidine triphosphate with regard to the phosphorylation of Ara-C. 
From these data it can be concluded that high intracellular 
levels of cytosine arabi nos i de triphosphate have no effect on 
further drug phosphorylation. 
The uptake and in-vivo phosphorylation of Ara-C in host tis­
sue and leukaemic cells in murine leukaemia (L1210) has been stu­
died by Chou et al., 1975). One hour after intraperitoneal in­
jection of labeled Ara-C the amount of free Ara-C in blood, small 
intestine and leukaemic cells was equal. However, the Ara-CTP of 
the leukaemic cells versus blood was more than 700 fold, while the 
Ara-CTP ratio of the small intestine versus blood was 24 fold. 
The inhibition of DNA synthesis was higher and more pronounced 
when higher levels of Ara-CTP were found in the cell. This study 
indicates that the differences in phosphorylation capacities 
between various cell types determine the chemotherapeutiс activ­
ity of the drug. 
Dephosphorylation of cytosine arabinoside 
The rate of cytosine arabinoside triphosphate dephosphoryla-
tion was not well studied. It is assumed that the nucleoside tri­
phosphatases and di phosphatases are high in activity compared 
with the monophosphatases. Thus, the rate determining dephosphory-
lation step is the Ara-CMP to Ara-C conversion (Schrecker, 1970), 
The rate of dephosphorylation of Ara-C nucleotides could be a 
factor in the response to Ara-C. However, in drug sensitive and 
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drug insensitive tumors no difference in the monophosphatase 
activity was found (Drahovsky et al., 1970; Schrecker, 1 9 7 0 ) . 
Deamination of cytosine arabinoside 
The inactivation of Ara-C by an enzyme catalyzed deamination 
was first reported to occur in Escherichia Coli (Pizer et al., 
I 9 6 0 ) . The enzyme, cytidine deaminase, is naturally occurring and 
deaminates cytidine and Ara-C to uridine and uraci1-arabinoside 
(Ara-U) respectively. In man a wide variation exists between the 
enzyme activities in different tissues. Highest activity has 
been found in the liver (Camiener, 1967; Ho, 1 9 7 1 ) . 
The biochemical properties of purified preparations of cytidine 
deaminase obtained from normal peripheral granulocytes and periph­
eral leukaemic blast cells have been studied by Chabner et al. 
( 1 9 7 4 ) . They found that the affinity of the enzyme for its physio­
logic substrate cytidine was higher than for Ara-C. They also 
found that the concentration of enzyme per mg protein was sig­
nificantly higher in the normal peripheral granulocytes (3.52 
3 
+ 1.86 χ 10 U/mg protein) than in the leukaemic blast cells 
3 
from AML patients (0.19 + 1.17 χ 10 U/mg p r o t e i n ) . After sepa­
ration of normal bone marrow cells into mature and immature frac­
tions by Ficoll density centri fugati on the enzymatic activities 
were determined in each fraction. It appeared that the cytidine 
deaminase activity in lysates of the mature fraction was 3.55 -
14.2 times greater than the activity found in lysates of the 
immature fractions. The authors stated that the amount of cytidi­
ne deaminase activity is related to the process of granulocyte 
maturation. A potent inhibitor of cytidine deaminase is tetra-
hydro-uridi ne (THU) (Camiener et a l . , 1968; Mulligan et al., 
1968; Ho et al., 1971; Chabner et al., 1 9 7 4 ) . 
2.2.4. The relation between intracellular enzymatic activities 
and res i stance to cytosi.ne_arabi.nqsi.de · 
The phosphorylation of Ara-C to its triphosphate is an essential 
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precondition to its function as inhibitor of DNA synthesis. In 
both human and mouse leukaemic cells the response to Ara-C has 
been correlated with the ability to accumulate cytosine arabino-
side triphosphate (Kessel et al., 1969; Chou et al., 1973). Resis-
tance to this agent may be the result of a decreased phosphoryla-
ting activity (Chu et al., 1965; Creasey et al., 1968) and/or 
an increased deaminating activity (Steuart et al., 1971; Chabner 
et al., 1974). Thus the therapeutic efficacy of Ara-C under phar-
macological conditions will be influenced by a) the total amount 
of drug transported into the target cells and b) the relative 
proportions of the drug activated by phosphokinases (K) and inac-
tivated by deaminases (D) expressed as a K/D ratio. 
A wide range in the ability of intact peripheral and bone marrow 
leukaemic blast cells to phosphorylate or deaminate the drug has 
been found (Ho et al., 1973). These findings were confirmed in 
partially purified enzyme extracts of peripheral blast cells from 
AML-patients (Chabner et al., 1974; Coleman et al., 1975). 
The broad range of the deaminating and phosphorylating abilities 
of AML cells is reflected in the variability of the calculated 
K/D ratio. 
It appeared that the K/D ratio in peripheral blast cells was of 
little value in predicting the response of AML patients to Ara-C 
(Coleman et al., 1975; Smyth et al., 1976). 
The large variation in the phosphorylating ability of the blast 
cells may be due to the large individual differences in the per-
centage of proliferating cells in the bone marrow as well as in 
the peripheral blood (Hillen et al., 1975). 
The deaminating activity of the blast cells in the bone marrow 
seems to be important. In clinical studies Steuart and Burke 
(1971) suggested that the pretreatment level of cytidine deami-
nase in the blast cells of AML patients determines the response 
to Ara-C. 
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CHAPTER 3 
A SENSITIVE BIO-ASSAY FOR PHARMACOKINETIC STUDIES OF CYTOSINE 
ARABINOSIDE IN MAN 
ABSTRACT 
A sensitive bio-assay is presented for the determination 
of plasma levels of cytosine arabinoside (Ara-C). The test is 
based on the inhibition of the incorporation of tritiated 
thymidine into DNA of rat bone marrow cells in the presence of 
Ara-C. The accuracy and the sensitivity of the test is demonstrated. 
Unknown plasma concentrations of Ara-C as low as 0.003 mg/1 
can be measured. 
The plasma disappearance curve of Ara-C after an intravenous 
2 
bolus injection in a dose of 100 mg/m , is biphasic. 
The half-life values of these two phases vary for individuals 
which is illustrated in two patients with acute leukaemia in 
which the plasma half-life of Ara-C in the first phase was 1.8 and 
1.4 minutes, and in the second phase 16.0 and 9.2 minutes 
respecti vely. 
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3.1 INTRODUCTION 
The pyrimi di ne analog cytosine arabinoside (Ara-C) has proved 
to be effective in the treatment of acute myeloblastic leukaemia 
(AML) in man. The therapeutic effect of Ara-C strongly depends on 
the dosage and the way of administration. Complete remission is 
obtained in more than half of the patients treated with Ara-C in 
combination with other drugs like thioguanine (Clarkson, 1972) 
or daunorubicin (Crowther et a l . , 1 9 7 3 ) . 
To achieve optimal treatment s c h e d u l e s , knowledge of pharmacolo­
gical p a r a m e t e r s , such as plasma half-life and effective drug-
concentration in relevant tissues, is required. Baguley et al. 
(1971) report a significant correlation between a short half-life 
of Ara-C in plasma and a poor response. 
The drug is eliminated by glomerular filtration and by enzymatic 
deamination to uraci1-arabinoside ( A r a - U ) . Between 87% and 91 % 
of the radioactivity recovered in the urine after intravenous 
3 
administration of tritiated cytosine-arabinos i de ( HAra-C) 
appeared to be Ara-U (Creasey et a l . , 1 9 6 6 ) . The enzyme responsi­
ble for deamination of Ara-C is deoxycytidi ne deaminase present 
in the human liver, spleen, plasma and in other tissues 
(Camiener, 1 9 6 7 ) . Individual variations in intra- and/or extra­
cellular deaminase activity may be responsible for the observed 
differences in half-life of Ara-C. 
Several methods for the determination of Ara-C in plasma have 
been published (Borsa et a l . , 1969; Hanka et a l . , 1 9 7 0 ) . 
Baguley and Falkenhaug (1971, 1975) described a bio-assay based 
on the inhibition of tritiated thymidine ( HTdR) incorporation 
into DMA of mouse L-cells and spleen cells,or ascitic L-1210 
cells in the presence of Ara-C. Concentrations as low as 
0.04 mg/1 plasma could be detected. 
The plasma disappearance curve of Ara-C after a single intravenous 
injection is biphasic when plotted on a semi 1ogarithmiс scale as 
is shown by Ho and Frei (1972) after injection of HAra-C. 
In various treatment schedules of AML a bolus injection of 100 mg 
2 
Ara-C/m /12 hours is given. To study interindivi dual differences 
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in the second phase of the elimination curve of Ara-C after a 
2 
therapeutic dose of 100 mg/m , it was found necessary to develop 
a more sensitive assay than those described till now. 
In this paper an assay is presented based on the inhibition by 
3 
Ara-C of HTdR incorporation into DNA of rat bone marrow cells. 
Plasma concentrations as low as 0.003 mg/l can be measured. 
3.2 MATERIALS AND METHODS 
Pr?ßaratign_of_bloQd_sa|TiQles 
Blood samples are taken just before and at different time 
intervals after a rapid injection of Ara-C in a dose of 100 mg/m . 
Blood samples of 8 ml are collected within 10 seconds in pre-
cooled tubes containing 150 ID Heparin and 50 ^g T e t r a h y d r o u r i -
dine and put on ice immediately. Tetrahydrouridi ne ( T H U ) , added 
to prevent enzymatic deamination of Ara-C (Camiener, 1 9 6 7 ) , was 
kindly provided by Dr Harry B.Wood, Chief Drug Development 
Branch, Division of Cancer Treatment, National Cancer Institute, 
Bethesda. 
The blood samples are centrifuged at 0 0C (2000xg, 15 min) and the 
plasma is ultraf i 1tered by cent ri fugati on at 0 С (250xg, 60 min) 
through conical ultrafilters (Centriflo F 25, A m i c o n ) . The ultra-
filtered plasma samples are stored at -70 С 
Preparation of the cell suspension 
Wistar rats are sacrificed and bone marrow is obtained from 
both femurs by expulsion with Eagle's Minimal Essential Medium 
(MEM Gibco, Cat. No. F 1 4 ) . The cells are suspended and filtered 
through a nylon filter (pore size ΙΟΟμιη) to remove tissue particles 
and cell-clumps. The cell number is counted electronically (Coulter 
Counter ZF) and the cell suspension is diluted to a density of 
2 χ 1 0 6 cells/ml in MEM containing 20 t foetal calf serum (Flow 
Lab.) buffered with 0.02 M Tris-HCl to pH 7.3 and supplemented 
_ 3 
with Spinner salts (Gibco F-15) and 2 χ 10 M 1-glutamine 
( S c h w a r z / M a n n ) . 
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Determination of Ara-C. 
Rat bone marrow cell suspension (0.5 ml, 2 χ 10 cells/ml) 
is added to 0.5 ml cooled ultraf11tered plasma containing 0.6 
3 3 
nmol (methyl- H)-thynndine ( HTdR, 1.66 Ci/mmol, Amersham). The 
samples are incubated at 37 С in a shaking waterbath for 150 min. 
After incubation the samples are placed on ice and centrifuqed 
(lOOOxg, 15 m m ) . The sediment is washed three times with 1 ml 
Krebs Ringer solution buffered with 35 χ 10 M Tris-HCL to pH 
- 3 
7.3 and containing 0.25 χ 10 M 2-deoxythymidi ne. To remove all 
acid soluble radioactivity the cells are washed twice with 1 ml 
IM HC10.. The residual HC10. is removed by treating the precipi­
tate with ice cold 99 % ethanol. 
The sediment is dissolved in 0.2 ml Hydroxide of Hyamine (Pack­
ard) and quantitatively transferred to counting vials with 4 ml 
distilled water. After addition of 6 ml Instagel (Packard) the 
radioactivity is counted in a liquid scintillation counter (LKB 
81000)and expressed m désintégration per minute (DPM). 
3.3 RESULTS 
^E^£lfli_§ffÇÇÎ-?f-ïâClQUS-t!ul!!I[!_p]3sma_samp]es_on__H-thymidine 
Д 0С9ГР2Г§$2 o n · 
Experiments were performed to exclude differences in thymi­
dine incorporation into DNA of rat bone marrow cells due to 
aspecific effects of human plasma. As is shown in fiq 3.1 the 
3 
incorporation of HTdR into DNA varies considerably after incuba­
tion with different plasma samples This phenomenon was observed 
in healthy individuals as well as in l e u k a e m c patients. Removal 
of plasma proteins by ultrafiltration through Centriflo ultrafil-
ters abolished this variability in all samples almost completely 
3 
and resulted in higher incorporation of HTdR. 
In control experiments with HAra-C, binding to plasma proteins 
and adsorption to the filter was found to be negligible. 
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The incorporation rate of HTdR into DNA of rat bone marrow 
cells depends strongly on conditions during incubation. It is 
found that the incorporation per hour increases after addition 
of different amounts of foetal calf serum. A concentration of 
20 % is found optimal causing an increase in incorporation of 
30 % compared to the control value (fig 3 . 2 ) . 
In fig 3.3 it is shown that in the abscence of Ara-C a linear 
3 
relationship exists between the incorporation of HTdR into DNA 
and time. However, after 90-120 min the incorporation rate seems 
to decline. The same figure demonstrates that the incorporation 
3 
of HTdR is inhibited in the presence of different amounts of 
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Fig 3.3 
Тпао рогаЬгоп о ƒ HTdR into DÍ1A of 10 rat bone marrow cells 
after different time inte ovals. 
To the oell suspension in MEM an equal amount of ultrafiltered 
plasma was added, containing different amounts of Ara-C (concen-
tration range 0-5 mg/l). 
3 
Ara-C. It can be seen that the incorporation rate of HTdR is 
inhibited proportionally to the Ara-C concentrations. A hiqh 
3 
concentration of Ara-C (5 mg/l) inhibits the HTdR incorporation 
almost completely within 30 minutes while a low concentration 
of Ara-C (0.02 mg/l) does not yet inhibit DNA-synthesi s com-
pletely after two hours of incubation. 
The determination of the calibration curve 
The inhibition of HTdR incorporation in the presence of 
Ara-C can be expressed as an inhibition percentage (IP); 
IP = Гі - -g- ] χ 100 i (1) 
з 
In formula (1) A is the incorporation of HTdR in the presence 
of Ara-C and В the HTdR incorporation without Ara-C. 
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3 The percentages of inhibition of IITdP incorporation into DHA of 
10 rat bone marrow cells is plotted versus the final Ara-C 
concentrations. The data are obtained with bone marrow from two 
different rats (Ο,Φ) using the same Ara-C solutions. The curves 
are obtained by calculating pararne ters a and b from equation (2) 
in a least squares procedure. 
For the determination of unknown concentrations of Ara-C a cali­
bration curve is made by plotting the inhibition percentages 
versus the logarithm of known Ara-C concentrations. The IP's 
are measured in triplicate for concentrations < 0.05 mg/1 and in 
duplicate for higher concentrations. 
The known concentrations are prepared in ultraf i 1tered plasma 
samples and their IP's are fitted in a least squares procedure 
to the equati on : 
IP 100 
a[Ara-Cj' 
1 e - a [Ara-Ci ) (2! 
The mathematical derivation and the meaning of parameters a and 
b are explained in the "appendix". A change in parameter a is 
related to the horizontal shift of the calibration curve and Ъ 
is correlated with the slope of the steepest part of the S-curve 
37 
Fig 3.4 demonstrates the experimentally determined inhibition per­
centages plotted versus the known concentrations of Ara-C. It 
also shows the calculated curve after determination of parameters 
a and b. The theoretical curve fits the experimental data rather 
well which gives an indication for the validity of the model 
from which equation (2) has been derived (see a p p e n d i x ) . 
The accuracy of the determination of unknown Ara-C concentrations. 
The shape of the calibration curve depends on the sensitivity 
of rat bone marrow cells for Ara-C. To test this biological varia­
tion in sens i ti vity,f i ve calibration curves were processed with 
one set of known Ara-C concentrations and the bone marrow of five 
different rats. The parameters a and b and their standard devia­
tions calculated for these curves are listed in table 3.1 
Rat 
1 
2 
3 
4 
5 
SD a SD Ъ 
9.5 
8.1 
9.8 
12.2 
10.0 
1.2 
0 . 7 
0 . 4 
0 . 8 
2 . 1 
0 . 5 8 
0 . 5 7 
0 . 5 6 
0 . 5 5 
0 . 6 7 
0 . 0 4 
0 . 0 3 
0 . 0 1 
0 . 0 2 
0 . 0 8 
Table 3.1 
Parameters a and b (equation 2) and their standard deviations (SO) 
calculated from five calibration curves processed with one set 
of known Ara-C concentrations and the bone marrow of five 
different rats. 
For the analysis in the least squares procedure it was not found 
necessary to use a weighting scheme for the average IP's of 
duplicate (high concentrations) and triplicate (concentrations 
« 0.05) measurements. 
The calibration curve processed with the use of bone marrow of 
rat 2 and 4 are plotted in fig 3.4. 
38 
The two curves are significantly different, indicating a variation 
in sensitivity of the bone marrow cells for Ara-C. Therefore accu­
rate determinations of unknown concentrations will only be obtained 
if they are processed in the same bone marrow cell suspension as 
used for the calibration curve. 
To get an estimate of the accuracy of the assay we calculated the 
standard deviation of the logarithm of an Ara-C concentration 
determined in the plasma of a patient. For this particular calibra­
tion curve the parameters a and Ъ are 8.75 (SD 0.56) and 0.52 
(SD 0.02) respectively. An inhibition percentage of 50 % (SD 2 t) 
corresponds here to a concentration of 0.076 mg/1 with an error 
margin of 0.126 and 0.044 mg/1 respectively (95 % confidence level), 
In the experiments unknown concentrations are measured in dupli­
cate which reduces the error margin to 0.110 and 0.052 mg/1 re­
spectively . The value 8.75 for parameter a is rather low (table 3.1) 
and corresponds to a relatively insensitive rat bone marrow. 
Since in the outer parts of the S-curve (IP > 80 % and < 20 %) the 
relative errors will increase, it is necessary to dilute the high 
concentrations to bring them in the linear part of the calibration 
curve. Higher values for parameter a do not change the slope of 
the straight part of the calibration curve. Therefore the relative 
error will not decrease but lower concentrations can be determined. 
Parameter Ъ affects the slope of the S-curve. High values for Ъ 
correspond to steeper curves which therefore reduce the relative 
errors in the measured concentration. 
ît!§_sensit].v].ty_gf_the_assa^ 
Fig 3.3 shows that the sensitivity of the test increases with 
the incubation time, which can also be concluded from the mathe-
matical approach (see appendix equation (6)). 
However, fig 3.3 also demonstrates that the incorporation of 
3 
HTdR declines after 90 minutes of incubation which limits the 
increase in sensitivity and also affects the accuracy. After an 
incubation time of 150 minutes, a compromise between sensitivity 
and accuracy, the lower limit of the assay proves to be 
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Fig 3.5 
The percentages of inhibition of HTdR incorporation into DNA of 
10 bone marrow cells is plotted versus the Ara-C concentrations. 
Calibration curve 2 is obtained after incubation of the cell sus-
pension with HTdR and Ara-C for two hours. 
Calibration curve 1 is obtained after preincubation of the cell 
suspension with Ara-C for one hour followed by another hour of 
incubation with HTdR. 
0.003 - 0.008 mg/1 depending on the sensitivity of the bone 
marrow. The incorporation of HTdR in the presence of Ara-C 
decreases as a function of time. Therefore, preincubation with 
3 
Ara-C in the absence of HTdR will increase the sensitivity of 
the assay. In fig 3.5 it is shown that preincubation with Ara-C 
3 
for one hour followed by incubation with HTdR for another hour 
indeed increases the sensitivity of the assay considerably. 
Assay_of_c^tos^ne_arab[nos^de_^n_human_g^asma. 
After an intravenous bolus injection of Ara-C in a dosage 
2 
of 100 mg/m blood samples were taken every 2 minutes during 
the first 10 minutes and every 5 minutes during the next 50 
minutes. After ultrafiltration the duplicate samples of the 
unknown concentrations and the samples for the calibration curve 
are incubated with the same rat bone marrow cell suspension. 
2 no preincubation 
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10 20 30 40 50 60 
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F i g 3.6 
Plasma disappearance of Ara-C in two AML-patients after an intra-
2 
venous push injection (100 mg/m ) . At different times blood was 
taken and Ava-C determined in the ultra filtered plasma samples. 
From these daza, half life values were calculated using a two 
compartment open model. 
The samples collected in the first 10 minutes after the injection 
of Ara-C are diluted three times with ultraf i 1tered plasma 
containing no Ara-C to bring the concentration in the linear part 
of the calibration curve. 
Fig 3.6 shows a biphasic elimination pattern of Ara-C from the 
blood in two AML patients before treatment. The curves are fitted 
with a least squares procedure to a two compartment open model to 
calculate the plasma half-life of Ara-C. The half-life values 
of the two phases are 1.4 (SD 0.1) and 9.4 min (SD 0.4) for patient 
A and 1.8 (SD 0.2) and 16.0 min (SD 1.8) for patient B. 
Weighting scheme based on a constant relative error in the 
measured concentration. 
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3.4 DISCUSSION 
The assay of Ara-C described in this paper does not require 
tissue culture facilities (Baguley et al.,1971) or tumor transplan­
tation (Baguley et al., 1975) and is more sensitive. The test is 
based on the inhibition of HTdR incorporation in the presence of 
Ara-C. 
It has been reported that the sensitivity of cells to Ara-C corre­
lates with their metabolic activities (Ho et al., 1973). The drug 
is either phosphorylated to its monophosphate by deoxycytidi ne 
kinase (К) (Chu et al., 1965; Momparler et al., 1971) and further 
phosphorylated to its triphosphate (Ara-CTP) or deaminated to 
uracil arabinoside by deoxycytidi ne deaminase (D) (Chabner et al., 
1974). The active intracellular form of Ara-C is Ara-CTP causing 
inhibition of DNA synthesis most likely by inhibition of DNA 
polymerase (Momparler et al., 1972). The inhibition of DNA synthe­
sis is greater and more pronounced at higher levels of Ara-CTP. 
Sensitive cells possess high К activities and low D activities 
(Ho et al., 1972; Furner et al., 1975). We therefore assume 
that the high sensitivity of rat bone marrow cells to Ara-C 
is due to a high K/D ratio. 
The accuracy of the test is cal cul ated usingthe mathematical ap-
3 
proach of the interaction between the HTdR incorporation into DNA 
3 
and the inhibition of the HTdR incorporation by Ara-C which is 
elaborated in this paper. The lower limit of the assay was 0.003 
mg/1 pi asma. 
In general the assay appears to be sufficiently sensitive to de­
termine the plasma disappearance of Ara-C in patients. In the 
case of a high elimination rate, the assay can be made more 
sensitive at lower concentrations by a slight modification. It 
is shown in fig 3.5 that preincubation with Ara-C indeed increases 
the sensitivity of the assay considerably. However, preincubation 
requires exact timing of the second incubation and therefore com­
plicates the method considerably, since for the determination of 
one single disappearance curve about sixty samples have to be 
processed. 
42 
For this reason this modification is restricted to selected cases 
After an intravenous bolus injection of Ara-C the shape of the 
elimination curve in plasma appears to be biphasic (fig 3 . 6 ) . 
The first phase mainly represents the rapid distribution of the 
drug over the total body water and the second phase reflects 
the elimination of the drug. Individual differences in the 
elimination rate correlate with the olasma half-life of the 
second phase. 
In this paper it is shown that a significant interindividual 
difference may exist in the plasma half-life of Ara-C, after a 
2 
bolus injection in a dose of 100 mg/m . 
Dosage schedules for Ara-C related to body weight or body sur-
face, such as used in treatment protocols in acute leukaemia, 
do not take into consideration large variations in the elimina-
tion rate of the drug. In a number of patients treatment with 
Ara-C must be either ineffective or toxic. It is to be expected 
that the results of leukaemia treatment will improve when the 
dosage of Ara-C can be related to optimal plasma levels during 
therapeutic courses. 
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APPENDIX 
3 
The relation between the inhibition of HTdR incorporation 
and the concentration of Ara-C expressed in equation (2) is 
derived from a model of two integrated processes. One process 
represents the incorporation of tritiated thymidine into DNA of 
rat bone marrow cells (DNA ) with the incorporation rate con­
stant к 
DNA
c
 +
 JHTdR -^ DNA (labeled DNA) (3) 
Since HTdR is available in excess,(3) can be described as: 
d
 (DNA*) = k. · DNA
r
 (t) (3a) 
dt i c 
where ki = k
o
 · [ 3HTdR]. 
The other process represents the inhibition of DNA synthesis by 
Ara-C with a rate constant k2 
ко 
DNA + Ara-C 
с 
-> DNA. (inhibited DNA) (4) 
It can be concluded from fig 3.3 that the inhibition of DNA 
synthesis in the presence of Ara-C is not linearly proportional 
to the Ara-C concentration. Therefore a parameter Ъ is introduc 
to approach this relation; 
d (DNA C) 
dt 
;2 · [Ага-СГ · t (4a; 
After integration it follows that the DNA-synthesis declines ex 
ponenti ally in time : 
DNA
c
 (t) = DNA 0 •k2 [Ага-СГ · t (5! 
DNA represents the initial number of rat bone marrow cells. 
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After introduction of (5) in (За) the rate of labeled DNA 
synthesis is derived. 
¿лтл
 = k l . DNAo . e-
k2 [ A ^ - c ] ¿ · t
 (6) 
Equation (6) is integrated over the incubation time and sub-
stituted into (1) to give ( 2 ) . 
From (6) it is obvious that the time for complete inhibition is 
h 
i n v e r s e l y p r o p o r t i o n a l t o [Ara-C] which i s i n good r e l a t i o n 
w i t h the e x p e r i m e n t a l f i n d i n g s (b = 0.5 - 0 .6 ) 
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CHAPTER 4 
PHARMACOKIN-ETICS 'OF CYTOSINE ARABINOSIDE IN 
ACUTE MYELOID LEUKAEMIA 
ABSTRACT 
In fourteen patients with acute myeloid leukaemia (AML) the 
plasma concentrations of cytosine arabinoside (Ara-C) were deter-
mined at the start of the first course of treatment at various 
intervals after a bolus injection. In ten patients plasma concen-
tration time data were fitted to a biexponenti al equation and 
pharmacokinetic parameters were estimated from the coefficients 
and exponents of such equations. The plasma half-life value of 
Ara-C of the first phase varied from 1.2 to 1.9 minutes with a 
mean of 1.6 minutes. The half-life value of the second phase 
varied from 8.8 to 18.9 minutes. 
All patients were treated with Ara-C alone in a dose of 100 mg/m 
for 10 or 14 days. A poor treatment response was observed in 5 
patients with second phase plasma half-life values of Ara-C 
ranging from 6.6 to 10.7 minutes. A complete remission was at-
tained in 9 patients with half-life values exceeding 12.7 minutes. 
In three patients plasma Ara-C concentrations were measured 
during constant rate infusion of different amounts of drug. It 
appeared that the plateau concentrations were directly proportion-
al to the dose, which indicated that in the therapeutic range 
no enzyme capacity-limited elimination occurs. 
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4.1 INTRODUCTION 
Cytosine Arabinoside (Ara-C) is one of the most powerful 
drugs in the treatment of acute myeloid leukaemia (AML). With 
several treatment protocols a complete remission can be obtained 
in more than 50 % of the patients (Clarkson, 1972; Mathé, 1 9 7 6 ) . 
The drug is transported from the extracellular fluid into the 
cell by a carrier-mediated diffusion process which increases the 
rate of uptake (Mulder et ál., 1 9 7 5 ) . Intracel 1 ul arly the drug 
is deaminated to uracil arabinoside (Ara-U) or phosphorylated to 
arabinosyl cytidine triphosphate (Ara-CTP). Only as Ara-CTP is 
the drug active and competes with deoxyribosylcyti di ne triphos-
phate (dCTP) for the binding sites on DNA polymerase, resulting 
in inhibition of DNA synthesis (Graham et al., 1 9 7 0 ) . In murine 
leukaemia it has been demonstrated that the level of Ara-CTP in 
the cell and the time during which it is present, determine the 
chemotherapeutiс effect of the drug (Chou et al., 1 9 7 5 ) . The 
level of Ara-CTP reached in these cells depends in the above-
mentioned enzymatic activities and the exposure time of the 
cells to a presumed minimal effective concentration in the extra­
cellular fluid. 
The therapeutic effect of Ara-C alone in the treatment of AML 
largely depends on the dosage and the mode of administration 
(Ellison et al., 1 9 6 8 ) . In a computer model (Mellett, 1972) based 
on the elimination studies performed by Ho et al. (1971) and 
continuous infusion studies of Ellison et a l . ( 1 9 6 8 ) , serum levels 
of Ara-C were calculated and related to the therapeutic response 
in adult patients with AML. It was concluded that a minimal effec­
tive serum concentration of Ara-C between 0.01 and 0.1 mg/1 must 
be maintained for a sufficiently long period in order to obtain 
a maximal effect. Differences in the rate of elimination of Ara-C 
and therefore in blood levels may be the cause of therapeutic failure. 
The plasma disappearance of Ara-C in man has been determined in 
several studies, and wide variations exist in the calculated 
plasma half-life values between the investigators (Creasey et al., 
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1966; Ho et al., 1971; Momparler et al., 1972; Baguley et al., 
1975). 
In this study 14 AML patients were treated with bolus injections 
of Ara-C. The plasma disappearance curves were determined after 
the first injection and plasma concentration time data were 
fitted to a biexponenti al equation. The pharmacokinetic parameters 
were estimated from the coefficients and exponents of such 
equations. The relation between the plasma half-life and the 
results of remission inducing therapy was examined. 
4.2 MATERIALS AND METHODS 
Patients 
Fourteen AML-patients were studied; six males and eight 
females. The mean age was 42 (ranging from 20 to 6 6 ) . The diag­
noses were confirmed at the W.H.O. Reference Centre for Leukae­
mias, Villejuif, France and the Leukaemia Working Group in the 
Netherlands. 
Treatment 
Patients were treated with bolus injections of Ara-C at a 
2 
dose of 100 mg/m every 12 hours. The duration of treatment was 
adapted to the percentage of DNA-synthesizing cells (S-phase 
cells) in the bone marrow as measured at the start of therapy 
by pul se-суtophotometry (Hillen et al., 1975). Patients with 
less than 10 percent of S-phase cells were treated during 14 
days, while those with more than 10 percent of proliferating 
cells were treated for 10 days. 
The bone marrow response after a course of treatment was studied 
three weeks after the end of Ara-C therapy, when repopulated bone 
marrow could be expected. Complete remission was defined as a 
state of normal bone marrow cellularity (less than 5 °i blast 
cells) and normal peripheral blood values. A second course was 
given if partial remission (5 % < blast cells < 40 %) was 
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obtained after 10 or 14 days' treatment. In cases of failure 
(blast cells > 40 %) a second course was given with an increased 
dose of Ara-C combined with Adriamycin and Thioguanine. 
During and after Ara-C treatment patients were hospitalized in 
germ-poor isolation units and most patients received prophylactic 
antibiotic medication. All patients received supportive treatment 
with granulocytes and platelets concentrates during the aplastic 
phase. 
?І°9<!-§§ШБІІи9 
Eight ml blood samples were obtained by venipuncture, collect­
ed in pre-cooled tubes containing 150 IU Heparin and 50 pg Tetra-
hydrouridine and put on ice immediately. Blood samples were taken 
after the first bolus injection at the start of therapy, every 
2 minutes during the first 10 minutes and every 5 minutes during 
the next 50 minutes. Tetrahydrouridi ne, added to prevent enzymatic 
deamination of Ara-C (Camiener, 1 9 6 7 ) , was kindly provided by 
Dr. Harry Wood, Chief Drug Development Branch, Division of Cancer 
Treatment, National Cancer Institute, Bethesda, U.S.A. 
To avoid drug interference during determination of the Ara-C 
plasma disappearance, all comedication was stopped 12 hours before 
the drug was administered. 
Assay procedure 
Blood samples were centrifuged at 0 oC (2000xg, 15 m i n ) . The 
plasma was ultraf i 1tered at 0 0C (250xg, 120 min) through ultra-
filters (Centriflo F 25, Amicon) to remove the plasma proteins 
which disturb the assay (Chapter 3 ) . The fraction of Ara-C bound 
to plasma proteins was about 13 % (Chapter 5 ) . During filtration 
the protein bound drug retained in the filter. The free drug 
appeared in the ultrafiltrate and was measured in the assay. In 
control experiments with labeled Ara-C, adsorption to the filter 
was found to be negligible. The Ara-C concentrations in the 
ultrafiltrate were determined in a bio-assay based on inhibition 
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of tritiated thymidine incorporation in rat bone marrow cells 
as described in chapter 3. 
DNA of bone marrow cells binds proportionally the fluorescent 
dye ethidium bromide. The extent of fluorescence is determined in 
a eel 1 suspensi on by f 1ow-microf1uorometry (ICP-II, Phywé, Göttingen, 
West G e r m a n y ) . 
The distribution of the relative DNA content in the cells is 
plotted as a histogram. The percentage of diploid (2n) G,-cells, 
tetraploid (4n) G„ + M-cells and interploid (2n < DNA < 4n) 
S-phase cells was calculated from the DNA histogram by planimetry. 
'!í§tÍ!C|Mti.ca]__assessment _o f e χ ge rimen ta l_de ternn ne d _Ara- Ç_çqncen-
trat^ons . 
a) Bolus injection of Ara-C 
The plot of the logarithmic plasma Ara-C concentrations versus 
time appeared to be biphasic. This is rather typical for the 
distribution of drug in a two compartment open model. The plasma 
concentrati o.n in the central compartment can be obtained from 
the equation: 
C1(t) = A . e " a t + B . e " ß t (1) 
A and В are the hybrid constants for the function, α and 8 are 
the reciprocal time constants. Preliminary estimates of the para­
meters of equation (1) were obtained by graphical m e t h o d s , then 
data were fitted by non linear least squares regression using a 
suitable program and an IBM 370 computer. The least squares 
values of Α, α. Β, β, were utilized to estimate the pharmacokine­
tic parameters: V d s s > V j , C L p , V d a r e a ) k 1 2 , k 2 1 , k ^ , ( t i ) 0 and 
( t j ) . of the two compartment open model with elimination only from 
the central compartment (Uagner, 1 9 7 5 ) . For symbols see table 4.1. 
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b) Constant rate infusion of Ara-C 
During constant rate infusion, the drug is distributed over 
the two compartments and equilibrium is attained when the time of 
infusion is much longer than the reciprocal time constant β. The 
increase of drug concentration in the central compartment (C,) 
is calculated with equation (2) representing a two compartment 
open model where elimination occurs only from the central com­
partment (Wagner, 1 9 7 5 ) . 
'1 T.C1. 
1 'el -at ,-3t (2) 
D is total amount of drug administered 
Τ is the time of infusion 
4.3 RESULTS 
Bolus injection of Ara-C. 
Plasma concentrations of Ara-C after a bolus injection in a 
dose of 100 mg/m body surface area were measured in 14 AML 
patients at various intervals as indicated in "methods". The 
plasma disappearance curve determined in one of the patients is 
demonstrated in fig 4.1 The shape of the curve appears to be 
biphasic. Such a pattern is typical for a two compartment open 
model in which the drug equilibrates from a central compartment 
into a peripheral one and is only eliminated from the central 
compartment. The pharmacokinetic parameters of this model are 
calculated for 10 patients as indicated in "methods" and listed 
i η table 4.1. 
The plasma concentration fell rather rapidly during the first 
phase (tj) with half-life values ranging from 1.2 to 2.0 
minutes and more slowly during the second phase ( t J ) R with half-
life values ranging from 8.8 to 18.9 minutes. The mean rate of 
elimination of the drug (CI ) was 6.29 1/min ranging from 3.84 to 
10.08 1/min. 
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Table 4 I 
Plasma roncentratzon time data of 10 AMI patze 
the volume of the central compartment (ν
η
), the 
second compartment (kJ2, kz]) the rate constant 
(LI ) , the volume of dbstrzbulzon steady state 
area under the curve (VdaT,ea) and the half-lzfe 
curve (t¡í)a and (t%)„ respectzvely. 
nts wer" fztted to а Ъгрхропеп11 a 7 equatzon to estimate 
rate constants of drug transport between the fvrst and 
of еігтгпаігоп (k^^), the еігтгпаіьоп clearance constant 
(Vdss^' t h e огшп<' 0f dzstizbut-Lon calculated from the 
values of the ftrst and second phase of the elimnatzon 
plasma concentration 
(mg/1 log scale) 
Ara-C 170 mg iv 
A=976mg/ I c* = 0 455 mm"1 
B = 0 4 0 mg/l /3 = 0079 min"1 
tV2. = 88min 
0 0 1 
50 60 
time (min ) 
Fi gure 4 . 1 
Plotted are the plasma Ara-C conoentrations versus time after 
an intravenous bolus injection. The closed circles represent the 
experimental data and the drawn line the calculated curve (equa-
tion Í). The parameters А
л
 В, a and β can be derived from this 
curve as described in "methods". 
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Constant rate infusion of Ara-C. 
In three patients plasma Ara-C concentrations were measured 
during constant rate infusion of different amounts of Ara-C. The 
findings in one of the patients are shown in fig 4.2. It appeared 
that the plasma Ara-C concentrations measured were directly pro­
portional to the dose. Plateau levels were reached in about 60 
minutes with different doses. 
plasma concentration 
A r a - C (mg/l) 
C l p = 3 60 I mm"1 
β = 0 0 5 2 mm"' 
α . 0 4 5 mm"' 
k e i . 0 24 mm"
1 
D - BO mg 
D = 34 mg 
D . 1 7 mg 
І-4 
. . .J 
50 6 0 
time (mm) 
Fi gure 4.2 
Plotted ave the plasma Ara-C coneentrations versus time during 
constant rate infusion. The determination of Ara-C in plasma 
samples was performed in triplicate, and the average Ara-C con­
centration with its standard deviation is represented by the 
closed circles and the error bars respectively. The theoretical 
increase of the plasma Ara-C concentrations during constant rate 
infusion of a certain amount of drug (D) is calculated as indi­
cated under "methods" and represented by the broken lines. 
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With use of the pharmacokinetic parameters (CI , k
e
i> α a n^ P) 
obtained from the elimination curve after a bolus injection, theo­
retical plasma concentrations during constant rate infusion were 
calculated (see methods). As is shown in fig 4.2 the experimental 
and calculated plateau levels were in good agreement. 
-l^î'Ê.^rê^'-.^^l^.^ÊfirË-ËD^-ÏÎ-îbf.ÊD^of.Ê.îreatmen^çgurse. 
Remission inducing therapy with Ara-C in AML patients was 
administered in bolus injections every 12 hours. The drug levels 
were determined on the first and the tenth day of a treatment 
course in three patients. As shown in fig 4.3, no differences in 
drug levels were found after the first and twentieth administra-
tion of Ara-C. 
plasma concentration 
(mg/l log scale) 
u u i • 1 1 1 1 1 1 — ' о 
10 20 30 40 50 60 
time 
Figure 4.3 
Plotted ave the experimental and calculated concentrations 
Ara-C versus time after the first (o o) and the 20th (ь-л) 
injection during a treatment course in one patient. 
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?!]§r5Ê£°!slQËn£§.9f-^r§lÇ.iD-rËlËH9D_Î9-the_results_of_remission 
ÍQ^y£ÍD3-íb§!r§Ey 
Remission inducing therapy consisted in bolus injections of 
2 
Ara-C in a dose of 100 mg/m every 12 hours on 10 or 14 consecu-
tive days, depending on the proliferation activity of the bone 
marrow as measured by pulse cytophotometry (table 4 . I I ) . Results 
of therapy were studied three weeks after the end of a course and 
were defined as complete remission ( C R ) , partial remission (PR) 
or failure ( F ) , as indicated under "methods". 
In cases of failure a second and third course was given in combi-
nation with other drugs. These courses were not'included in this 
study. 
Patient 
L.T. 
J.H. 
H.C. 
P.S. 
J.K. 
C.A. 
O.S. 
N.T. 
J.W. 
Α.Λ. 
H.H. 
P.C. 
Ü.L. 
Α.Κ. 
Sex 
F 
M 
M 
M 
F 
Age 
29 
56 
61 
41 
43 
53 
23 
39 
46 
66 
28 
20 
31 
57 
Di agnos i s 
AML 
AMML 
AML 
AML 
AML 
AML 
AML 
AML 
AML 
AML 
A11 ML 
AML 
AMML 
AMML 
State of 
di sease 
Rel apse 
First 
First 
Fi rst 
First 
First 
First 
First 
First 
Rel apse 
First 
Rel anse 
Rel apse 
First 
" S phase 
cells 
6 
13 
11 
6 
10 
11 
9 
13 
N.D. 
12 
13 
12 
11 
15 
Treatment 
courses 
(days) 
14 
10 10 
10 6 
14 
10 
14 10 
14 
in 
7 10 
10 
14 
10 
10 14 
10 
Half life 
( t i ) B 
(min) 
18.9 
18.0 
17.4 
16.6 
15.5 
14.6 
14.3 
13.3 
12.7 
10.7 
η.5 
9.5 
8.8 
6.6 
Result of 
reni ssi on 
i nduction 
CR. 
CR. 
CR.. 
CR. 
CR. 
CR. 
CR. 
CR. 
CR. 
P.R. 
F 
F 
F 
F 
Table 4.II 
In 14 AML patients the relation between the half-life of Ara-C 
and the result of remission inducing therapy is presented. 
Complete remission (CR), partial remission (PR) and failure of 
therapy (F). AML patients are subdivided in acute myeloblastic 
leukaemia (AML·) and acute myelo-monoblastic leukaemia (AMML). 
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The p l i a r m a c o k i n e t i с parameters f t , ) , ( t , ) , , CI , V . , V . . 
v
 i'a v ¿'3 p d s s darea 
determined in 14 patients were studied in relation to the results 
of remission inducing therapy. The first group consisted of nine 
patients in which complete remission was attained. Five patients 
in the second group did not come in complete remission (table 
4 . I I ) . The average of the pharmacokinetic parameters with their 
range was calculated for each group (table 4 . I I I ) . Though the 
number of patients was small, it appeared that the average half-
life of the second phase of the elimination curve (t,) was 
г Ρ 
much longer in the first group compared to the second group of 
patients. The average values for the elimination clearance 
constant (CI ) and the volumes of distribution (V, and V. ) 
ρ
 v
 ds s darea' 
did not differ very much between the two groups. 
Pharmacokinetiс 
parameters 
Group I 
(n = 9) 
uroup II 
(n = 5) 
X 
range 
X 
range 
mi η 
1.53 
1.22 - 2.04 
1.49 
1.39 - 1.73 
(tj)
e 
mi η 
15.14 
12.73 - 18.91 
9.58 
6.57 - 10.86 
C 1 P 
Inin*1 
5.34 
3.84 - 10.OB 
5.99 
3.07 - 5.64 
Vdss 
1 
40.20 
32.62 - 93.38 
32.69 
16.73 - 43.60 
darea 
1 
95.41 
71.11 - 272.43 
85.14 
53.71 - 86.92 
Table 4.Ill 
The average of the pharrnacokinetia parameters with their range 
and the result of remission inducing therapy in two groups of 
patients is studied Group I aonsists of 9 patients who achieved 
complete remission and group II consists of 5 patients who 
achieved partial remission or failure. 
For abbreviations of the pharmacokinetic parameters see legend 
of table 4.1 
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4.4 DISCUSSION 
This study presents pharmacokinetic data on Ara-C in man, 
derived from the decline of plasma concentrations after a bolus 
injection. It appears that after the first distribution phase 
the plasma half-life values of the second phase in 14 AML patients 
range from 6.6 to 18.9 minutes. These results are in agreement 
with the data of Momparler et al. (1972) and Baguley et al. (1975). 
With the aid of tritium-labeled Ara-C, Ho et al. (1971) found 
a mean of 12 minutes for the first phase and 111 minutes for the 
second phase. These findings may indicate a third phase in the 
elimination curve of about two hours. It can be calculated 
(equation 2) that during constant rate infusion, equilibrium between the 
two compartments is approximated after at least three times the 
plasma half-1i fe. Al though the data in our infusion experiments 
(fig 4.2) indicate that equilibrium is attained after about one 
hour, the infusion time should be at least six hours to show the 
existence of a third phase in the order of two hours. Thus the 
possibility of a third phase remains open and in that case the 
half-life value of the first phase as reported by Ho et al. 
(1971) corresponds to the half-life values of the second phase 
in our experiments. 
Ara-C is eliminated by glomerular filtration and enzymatic 
deamination to non-toxic Ara-U (Camiener, 1967). Between 87% and 
91 % of the radioactivity recovered in the urine after intra-
venous administration of labeled Ara-C appeared to be Ara-U 
(Creasey et al., 1 9 6 6 ) . To exclude the possibility of an enzyme 
capacity-1 imi ted elimination as reported e.g. for salicylates 
(Levy et al., 1972) plasma concentrations of Ara-C were measured 
during constant rate infusion. It appeared that plasma concen-
trations in the therapeutic range from 0.1 up to 0.4 mg/1 were 
directly proportional to the dose (fig 4 . 2 ) . 
Prolonged administration of this drug might either reduce the 
plasma half-life as a consequence of increased metabolic elimina-
tion, as has been observed for rifampycin (Boman et al., 1 9 7 2 ) , 
or increase the blood level in case of accumulation when a long 
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third phase of at least six hours exists in the plasma dis-
appearance curve (Creasey et al., 1 9 7 6 ) . In order to exclude 
these possibilities the level of Ara-C was determined in three 
patients after the 1st and 20th dose. It appeared that drug level 
and rate of elimination remained unchanged (fig 4 . 3 ) . 
Since the effect of Ara-C probably depends on the exposure 
time of blast cells to an effective drug concentration in the 
extracellular fluid (Chou et al., 1 9 7 5 ) , we studied the relation 
between the results of the remission inducing therapy and the 
pharmacokinetic parameters determined in 14 patients. A complete 
remission was obtained in 9 patients with average plasma half-
life values of 15.1 minutes, and therapy failed in 5 patients 
with average half-life values of 9.6 minutes (table 4 . I I I ) . 
Although the number of patients is small, variations in the rate 
of elimination or degradation of Ara-C are probably important 
in predicting the results of chemotherapy. In patients with a 
short half-life it may be possible to enhance the therapeutic 
result, either by bolus injections with an increased dose or by 
continuous infusion to maintain effective drug levels for a 
sufficiently long time. 
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CHAPTER 5 
CYTOSINE ARABINOSIDE BINDING TO HUMAN PLASMA PROTEINS 
ABSTRACT 
The interaction of cytosine arabinoside (Ara-C) with human 
plasma proteins was investigated by means of ultrafiltration and 
ultracentri fugati on. The results obtained with both methods did 
not differ significantly. Ara-C binding was studied at plasma 
levels within the therapeutic range (0.005 - 1.0 m g / l ) . It 
appeared that 13.3 % (SD: 2.2 %) of Ara-C in the plasma was 
bound to proteins. The percentage of bound drug was independent 
of the drug concentration, at least in the therapeutic range. 
64 
5.1 INTRODUCTION 
Most drugs circulate in the blood, bound reversibly to plasma 
proteins. In general, an equilibrium exists between drug molecules 
free in solution and those bound to proteins. The unbound fraction 
of the drug is available for transport to the tissues and thus 
for therapeutic action (Davis, 1 9 4 3 ) . The bound drug is considered 
to be a reservoir. While the free drug is being eliminated, the 
bound drug dissociates from its binding sites and replenishes 
the supply of free drug. Variations in the extent of binding may 
result in significant changes in pharmacokinetic and pharmaco-
dynamic behaviour of drugs that are highly bound to plasma 
proteins (Anton, 1973; O'Reilly, 1 9 7 3 ) . 
Pharmacokinetic studies of the cytostatic drug cytosine arabinoside 
(Ara-C) in acute myeloid leukaemia (AML) showed the existence 
of significant variations in the elimination rate in different 
patients (chapter 3 ) . To investigate the cause of these differ-
ences we determined the fraction of Ara-C bound to plasma 
proteins at therapeutic drug concentrations. Since protein 
content and composition in the plasma of AML patients are normal, 
when determined by means of conventional assay methods, this 
paper reports the results of ultrafiltration and ultracentri fu-
gation studies in plasma samples of healthy volunteers. 
5.2 MATERIALS AND METHODS 
3 
Tritiated cytosine arabinoside (5- H Ara-C, 15 Ci/mmol, Radio-
chemical Centre, Amersham, England) more than 98 % pure, was used. 
The purity was confirmed by ascending thin-layer chromotography 
on silicagel glass plates (F257, Merck) using water saturated 
butanol as solvent (Scheit, 1 9 6 7 ) . 
The determination of the percentage of bound Ara-C was carried 
out with citrated plasma obtained from healthy volunteers. The 
drug was dissolved in therapeutic concentrations ranging from 
0.005 to 1.0 mg/1 plasma. Trace quantities of H Ara-C (0.04 
pCi/ml plasma) were added. Triplicate samples of 50 yl were 
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retained for the determination of total radioactivity The 
remainder was used in ultrafiltration and ultracentnfugati on 
studi es. 
Ul traf11tration 
Plasma samples of 4 ml were ultraf 11tered by centri fugati on 
at 0 oC, 250 χ g, through conical ultrafilters (Centriflo, F 25, 
Amicon) as described by Hooper et al.(1975). The experiments 
were performed at 0 С in order to prevent enzymatic conversion 
of the drug. From the first ultraf 11 trate (approximately 0,5 ml) 
triplicate samples of 50 ul were taken. The 50 μΐ samples of 
plasma and ultraf 11 trate were added to 10 ml scintillation fluid 
(Instagel, Packard) and were counted in a liquid scintillation 
counter (LKB 81000). The fraction of drug bound to plasma pro­
teins was calculated from the radioactivity in the ultraf 11 trate 
and in the original plasma samples. 
Since the amount of protein in the plasma samples varied, a 
correction was made for the volume displaced by the proteins 
according to McLean et al (1935) The radioactivity in all 
plasma samples was multiplied with a factor 100/P where 
Ρ = 99.6 - (0.75 χ I protein) ml/100 ml plasma. 
w 
Ul tracentn fugati on 
Ultracentnfugati on of plasma samples was performed in an 
IEC B-60 ultracentrifuge equiped with a swinging-out rotor (no 
SB 283) carrying 6 polyaliumer tubes (no 2842, contents 12 m l ) . 
Runs were made at 40,000 RPM (30,000 χ q ) , 0 oC for 16 hours 
according to Scholtan (1965). After centri fugation the content 
of each tube was collected in separate fractions from the top to 
the bottom. At the top 5 fractions of 0.2 ml were taken followed 
by 4 fractions of 0.5 ml and 9 of 1.0 ml. When runs were made at 
30,000 χ g, 0 С for 40 hours, fractions of 0.5 ml were taken. 
From each fraction triplicate samples of 50 yl were counted for 
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radioactivity. The percentage of bound Ara-C was calculated after 
correction for protein volume as described under u l t r a f i l t r a t i o n . 
In a separate tube, containing plasma without Ara-C, the same 
fractions were taken after centri fugati on. From each fraction 
and the original plasma, duplicate samples of 0.1 ml were analysed 
for protein content. 
Determination_of_protein 
Total protein concentrati ons were determined with the biuret 
method. The concentration of albumin in the plasma samples was 
determined with the bromcresol-green method according to Doumas 
et al. ( 1 9 7 1 ) . The globulin content was calculated by sub-
tracting albumin content from total protein. 
5.3 RESULTS 
Ul traf i 1trati on 
The fraction of Ara-C bound to plasma proteins is determined 
by ultrafiltration taking advantage of the fact that all bound 
Ara-C is retained in the filter and all free Ara-C will appear in 
the u l t r a f i l t r a t e . The extent of protein binding is calculated 
from the concentration of free drug in the ultrafiltrate and the 
concentration of total drug in the original plasma sample after 
correction for the volume displaced by the proteins as described 
in " m e t h o d s " . 
Different Ara-C concentrations in the therapeutic range (0.005-
3 
1.0 mg/1) with trace amounts of H Ara-C were added to plasma 
samples of four individuals and were ultraf i 1tered to determine 
the extent of protein binding. The results of these experiments 
are shown in table 5.1. The percentage of drug retained in the 
filter and probably bound to plasma proteins varies from 12.5 % 
to 14.0 % and appears to be independent of the drug concentration 
in the range studied. This assumed protein binding might be 
caused by adsorption of the drug to the filter m a t e r i a l . There-
fore, experiments were performed to exclude this possibility. 
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Ara-C 
concentration 
1 
0.1 
0.5 
0.05 
0.005 
(mg/l) 
A ra-C bound 
(%) 
12.5 
12.5 
13.8 
14.0 
13.8 
S.D. 
2.5 (4) 
2.1 (4) 
2.2 (4) 
2.2 (4) 
2.1 (4) 
Table 5. I 
The average percentage of drug bound to plasma proteins with 
standard deviation (SD) in plasma samples obtained from 4 
individuals (n=4) is demonstrated at different Ara-C aonoen-
traiions. Binding studies were performed by ultrafiltration. 
protein £% oFcontrol 1 
100 , 
Ara-C (% oFcontrol 1 
100 
Θ0 
6 0 
4 0 
2 0 
12 ml 
Fi gure 5.1 
Dis íribulion pattern of Ara-C and probein in the centrifuge tube 
after IS hours of centrifugation at 20,000 χ g, OC. 
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Ara-C (0 .05 mg/1) and t r a c e amounts o f H Ara-C were prepared 
i n plasma u l t r a f i l t r a t e and f i l t e r e d a g a i n . No s i g n i f i c a n t 
d i f f e r e n c e s in the r a d i o a c t i v i t y o f the u l t r a f i l t r a t e be fo re and 
a f t e r the second f i l t r a t i o n were f o u n d , i n d i c a t i n g a n e g l i g i b l e 
a d s o r p t i o n o f the drug t o the f i l t e r . 
yiír§CCDÍrlfy9§£Í9D 
The fraction of Ara-C bound to plasma proteins is also deter-
mined by ul tracentri fugati on. In these experiments the extent of 
protein binding is calculated from the concentration of free drug 
in the protein free fraction at the top of the centrifuge tube 
and the concentration of total drug in the original plasma sample. 
3 
Trace amounts of H Ara-C and Ara-C concentrations varying from 
0.005 to 1.0 mg/1 were added to plasma samples and centrifuged 
for 16 hours ar 30,000 χ g, 0 С. After een tri fugati on, fractions 
were taken and assayed for radioactivity and protein as described 
in "methods". The distribution of labeled Ara-C and protein in the 
centrifuge tube is demonstrated in a representative experiment 
in fig 5.1 A proteinfree supernatant of 0.75 ml and several 
fractions at which protein and drug are in equilibrium, have 
Ara-C Ara-C bound S.D. 
concentration (mg/ml) (%) 
1 
0.1 
0.5 
0.05 
0.005 
12.6 
13.4 
14.1 
13.5 
12.8 
2.6 (4) 
3.5 (4) 
2.3 (4) 
3.2 (4) 
2.9 (4) 
Table 5.II 
The average percentage of drug bound to plasma proteins uiLh 
standard deviation (SD) in plasma samples obtained from Ί 
individuals (n=4) is demonstrated at different Ara-C concentra­
tions. Binding studies uere performed by ultraoentrifugaiion 
at ¿0,000 χ g3 0°С, for 16 hours. 
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been found. These findings are in accordance with the data of 
Scholtan (1965) who studied protein binding of sulfonamides. 
The percentage of drug bound to protein in the plasma of four 
individuals varies from 12.6 % to 14.1 % and is independent of 
the drug concentration in the therapeutic range (table 5.II). 
Büttner et al. (1961) reported an increase in the concentration 
of unbound drug in the protein free supernatant after long 
lasting centri fugati on times. Fig 5.2 represents the distribution 
of drug and protein in the centrifuge tube after 40 hours of 
centri fugati on. 
The protein free supernatant is increased (3.5 m l ) . The protein con-
centration at the plateau level is decreased by 35 %. However, the 
percentage of drug in the proteinfree supernatant has not changed. 
protein (% oF con t ro l Ί 
100 
3 0 0 0 0 g - , 0 o C 4 0 h oFcentrr iFugrfhon 
А г л - С С ' о oF control ) 
15 7 
133 
110 
100 
во 
60 
4 0 
2 0 
ö 10 m l 
f r a c t i o n s 
Figure 5.2 
Distribution pattern of Ara-C and protein in the centrifvge tube 
after 40 hours of centri Гида Lion at 60,000 χ g, ОС. 
The protein aontaining fractions were analysed for albunin and 
globulins. 
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5.4 DISCUSSION 
The percentage of Ara-C bound to plasma proteins has been 
determined by ultrafiltration and ultracen tri fugati on . 
The principal advantages of ultrafiltration above ul tracentri fug-
ation are the economy of time and the ease of performance. 
The disadvantage of ultrafiltration may be the adsorption to the 
filter material. Moreover, an enhanced binding of the drug to 
plasma proteins in the filter seems reasonable due to increase 
of protein concentration during filtration (Olsen, 1975). 
Therefore protein binding was also studied by ultracentrifugati on 
in which both phenomena are absent. The results obtained with 
both methods are equal. The percent of Ara-C bound to plasma 
proteins amounts approximately 13 %. 
Scholtan stated that during ultracentrifugati on in a swinging-
out-bucket rotor the synchronous sedimentation of protein and 
protein-drug complex as well as the existance of a level where 
all components are in equilibrium has to be found. The concentra-
tion of drug and protein at the plateau level should be equal to 
the original concentration. In our experiments concentrations 
of drug and protein at the plateau level were somewhat lower 
compared with the original concentrations after 16 hours of 
centri fugati on (fig 5.1). This finding was more pronounced after 
40 hours of centri fugati on (fig 5.2). 
The sedimentation rate of the different plasma proteins depends 
e.g. on the molecular weight which differs markedly for albumin 
and globulins. After 40 hours of ultracentrifugati on the plateau 
level for proteins had almost vanished and determination of the 
protein containing fraction for albumin and globulins revealed 
a variation in the sedimentation rate of the different globulins 
(fig 5.2). The importance of proteinbinding in pharmacokinetics 
was recently studied for a n t i p y n n e , a drug with a protein 
binding comparable with Ara-C (Guqler et al., 1975). No signif-
icant changes in distribution and elimination of a n t i p y n n e were 
found in patients with normal and very low plasma albumin concent-
rations. We therefore may conclude that oroteinbinding is not 
a significant factor in the pharmacokinetics of Ara-C. 
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CHAPTER б 
THE RELATION BETWEEN THE ARA-C SENSITIVITY 
AND THE RESPONSE TO TREATMENT IN PATIENTS 
WITH ACUTE MYELOID LEUKAEMIA 
ABSTRACT 
A test is presented to predict the response of patients 
with acute myeloid leukaemia (AML) to cytosine arabinoside 
(Ara-C). This Ara-C sensitivity test is based on the in-vitro 
incorporation of tritiated thymidine ( HTdR) into leukaemic 
bone marrow cells taken before and one lour a f t e r an intra­
venous bolus injection of Ara-C. 
The decrease of the HTdR incorporation after Ara-C administration, 
expressed as an inhibition percentage, was determined in 11 AML 
patients and related to the result of remission inducing therapy. 
An inhibition percentage of more than 70 % was found in seven 
patients. All these patients came into complete remission after 
one or two courses with Ara-C alone. 
A relatively low inhibition percentage was found in four patients. 
Three of these patients failed on therapy after two courses and 
one patient died during the second course. Obviously Ara-C is 
not the most adequate cytotoxic drug for these patients. 
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6.1 INTRODUCTION 
Cytosine arabinoside (Ara-C) is an analogue of the naturally 
occurring nucleoside суti dine. The drug is widely used in the 
treatment of acute myeloid leukaemia (AML) often in combination 
with other drugs. Unfortunately only in about 60 % of the patients 
complete remission is attained (Clarkson, 1972; Crowther et al., 
1973; Mathé et al., 1976). 
After intravenous administration the drug passes the cell membrane 
and is either phosphorylated or deaminated (Chu et al., 1965; 
Camiener, 1967). Only in the form of Ara-CTP is the drug active. 
Presumably it inhibits DNA polymerase by competing with deoxy-
cytidine triphosphate for the binding sites on the enzyme 
(Graham et al., 1970). The intracellular amount of Ara-CTP is 
related to the duration of an effective drug level (Mellett, 1972) 
and to the net effect of the phosphorylating and deaminating 
enzymatic activities (Ho, 1973). 
In this paper an Ara-C sensitivity test is described based on the 
difference in HTdR incorporation into leukaemic bone marrow cells 
taken before and one hour after a bolus injection of Ara-C. The 
3 
inhibition of HTdR incorporation after Ara-C administration was 
measured in eleven AML patients and related to the results of 
remission inducing therapy. 
6.2 MATERIALS AND METHODS 
Patients 
Eleven AML patients were studied; three males and eight 
females. The mean age was 38 years ranging from 19 to 57 years. 
Eight patients were first treated and three patients were treated 
for a relapse. The diagnoses were confirmed at the W.H.0.Reference 
Centre for Leukaemias, Villejuif, France and the Leukaemia Working 
Group in the Netherlands. 
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Treatment 
All patients were treated with bolus injections of Ara-C in a 
2 
dose of 100 mg/m every 12 hours during the first remission indu-
cing course. This course was given for 10 - 14 days. The result of 
the first course was evaluated at the moment that the bone marrow 
was repopulated. Complete remission (CR) was defined as a state 
of normal bone marrow cellularity with less than 5 % of myelo-
blasts and an adequate peripheral circulatory count of polymorpho-
nuclear leukocytes and platelets. When the number of leukaemic 
cells in the bone marrow was between 5 % and 40 % the result of 
treatment was defined as partial remission (PR). No response to 
therapy in the bone marrow (more than 40 Í leukaemic cells) was 
defined as fai 1 ure (F). 
A second course was given when the first course resulted in a 
PR or F. In cases of a PR patients were treated with Ara-C alone. 
In cases of F patients were treated with Ara-C in combination 
with Adriamycin and Vincristine. In these patients the result 
of treatment was once more evaluated after the second course. 
During treatment patients were hospitalized in germ-poor isola-
tion units. All patients received supportive treatment with gran-
ulocytes and piateletsconcentrates during the aplastic phase. 
Differences in DNA content of bone marrow cells 
DNA of bone marrow cells binds proportionally the fluorescent 
dye ethidium bromide. The extent of fluorescence is determined 
in a cell suspension by f 1ow-microf1uorometry (ICP-11, Phywé , 
Gottingen, West Germany). 
The distribution of the relative DNA content in a large number 
of cells is plotted as a histogram. The percentage of diploid 
(2n) G^-cells, tetraploid (4n) G« + M-cells and interploid 
(2n < DNA < 4n) S-phase cells was calculated from the DNA histo-
gram by planimetry (Gohde, 1973) 
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IbË_ir§:Ç.§§G51îlïlî^.î§5Î 
The test is based on the in-vitro incorporation of HTdR 
into leukaemic bone marrow cells taken before and one hour after 
2 
an intravenous bolus injection of Ara-C in a dose of 100 mg/m . 
These marrow aspirates were taken from patients with a full blown 
leukaemia at the start of therapy. The cells were diluted in 2 ml 
of buffered ACD solution (acid citrate dextrose, pH 7.4, formula 
A, USP XV) and filtered through a nylon filter (pore size 100 μ™) 
to remove tissue particles and cell clumps. The number of nucleated 
cells was counted electronically (Coulter Counter Z.F.) and ad­
justed to 10 cells/ml with a solution of Krebs Ringer Tris (pH 
7.4) containing 5 % heat-inactivated (56 C) Foetal Calf Serum 
(KRT-5 % F C S ) . Twenty ml of this cell suspension was layered 
upon 10 ml Ficoll Isopaque containing 5 % FCS (spec. grav. 1.074 q/ml 
at 2 5 0 C ) according to Loos et al. (1974). After centri fugation 
(30 min, 1100 χ g, 0 o C ) the cells at the interface were collected 
by aspiration with a needle punched through the wall of the tube 
just below the interface. The cells (> 90% blast cells) were washed 
once with a solution of KRT-5 % FCS. After centri fugation (10 min, 
700 χ g, 0 С) the cells were resuspended in 1 ml KRT solution 
20 % AB serum and diluted to a density of 0,5 χ 10 c e l l s / H . 
Duplicate samples of 1 ml were incubated with 0.2 nmol tritiated 
thymidine ( HTdR, spec. act. 5 Ci/mmol) at 37 С for one hour in 
a shaking water bath. After incubation the samples were placed 
on ice to stop incorporation and centrifuged (1000 χ g, 15 min, 
0 С ) . The pellet was washed three times with 1 ml KRT containing 
-3 
0.25 χ 10 M 2-deoxythymidi ne. To remove all acid soluble radio­
activity the cells were washed twice with 1 ml IM HC10.. 
The residual HC10. was removed by treating the precipitate with 
ice cold 99 % ethanol. The sediment was dissolved in 0.2 ml 
hydroxide of hyamine (Packard) and quantitatively transferred to 
counting vials with 4 ml distilled water. After addition of 6 ml 
Instagel (Packard) the radioactivity was counted in a liquid 
scintillation counter (LKB 8 1 0 0 0 ) . The difference in HTdR incorpo­
ration into the blast cells before and after a d m m strati on of 
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Ara-C was expressed as an inhibition peroentage. The test is 
summarized schematically in fig 6.1. 
ARA-C SENSITIVITY TEST 
marrow aspiration 
Ara-C (100 mg/m ) 
0 min 
0.5 χ 10 
Leukaemi с cel 1 s 
1 ml 
suspens1' on 
narrow aspiration 
60 min 
0.5 χ IO 6 
leukaemi с cel 1 s 
'HTdR 
i neubat i on 
I 
thymidi ne 
i ncorporati on 
before Ara-C 
0.2 nmol 
60 min 37 С 
'HTdR 
incubati on 
I 
thymidine 
i ncorporati on 
after Ara-C 
100 % 
inhibí ti on 
percentage 
0 % 
Fi gure 6.1 
Schematic representations of the Ara-C sensitivity test. 
Leukaemic bone marrow cells, isolated by density centrifugation 
from marrow aspirates taken before and 60 minutes after Ara-C 
administration, were incubated with HTdR (37 C, SO min). The 
difference in the amount of incorporated thymidine is expressed 
as an inhibition percentage. The details are given in "Methods". 
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6 3 RESULTS 
B§ll§bility_of_the_Ara-C_sensit^vTty_test 
a) Recovery of leukaemic cells. 
Since erythrocytes disturb the Ara-C sensitivity test they 
were removed from bone marrow aspirates by centri fugati on on a 
Ficoll Isopaque cushion as described before. Although almost 
complete elimination of erythrocytes was achieved, some variable 
loss of leukaemic cells was unpreventable. 
In 5 patients the recovery and the possibility of a selective 
loss of proliferating cells was studied. Table 6.1 shows the 
recovery of leukaemic cells at the interface from marrow aspi­
rates taken before and after Ara-C The recoveries are almost equal 
in each individual oatient. However, the recovery between the 
different patienus varies This may be due to differences in 
specific gravity of the leukaemic cells (Zipursky et al., 1976). 
The individual differences in loss of leukaemic cells could in­
volve preferential loss of proliferating cells. For this reason 
the percentage of S-phase cells (2n < DNA < 4n) was determined 
by a f 1ow-microf1uorometer. In each patient the percentaoe 
of S-phase cells in the bone marrow aspirate taken before and 
after Ara-C appeared to be almost equal. Also after density 
cent ri fugati on no significant differences in the percentages 
of S-phase cells in the isolated leukaemic cells were found in 
individual patients. In patients with a rather low recovery, the 
percentage of S-phase cells in the suspension appeared to be 
increased after Ficoll Isopaque separation. This suggests 
that non-prolι ferating cells are preferentially lost during 
separati on. 
3 
b) Reproduceabi11ty of HTdR incorporation 
The reproduceabi11ty of HTdR incorporation was studied in 
three bone marrow aspirates. Each bone marrow aspirate was divided 
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into four samples and separated on Ficoll Isopaque. After centri-
fuqation the leukaemic cells were isolated and incubated with 
7 3 
HTdR. The average variation in the extent of HTdR incorporation 
was 4 % i η the four cell suspensions obtained from each bone 
marrow aspirate. 
P a t i e n t 
1 
2 
3 
4 
5 
Moment o f 
b o n e m a r r o w 
a s p i r a t i o n 
BEFORL ARA-C 
AFTER ARA-C 
BEFORE ARA-C 
AFTER ARA-C 
BEFORE ARA-C 
AFTER ARA-C 
BEFORE ARA-C 
AFTER ARA-C 
BEFORE ARA-C 
AFTER ARA-C 
R e c o v e r y o f 
l e u k a e m i c 
e e l I s a t t h e 
i n t e r f a c e 
80 % 
75 % 
6 7 % 
56 % 
75 % 
75 % 
89 % 
89 % 
58 % 
58 1 
P e r c e n t a g e o f 
Bone m a r r o w 
a s p i r a t e 
20 % 
18 % 
6 % 
6 % 
13 % 
12 % 
10 % 
11 t 
5 I 
5 % 
S - p h a s e c e l l s 
I s o l a t e d 
l e u k a e m i c 
c e l l s 
20 % 
19 % 
8 % 
9 % 
13 % 
14 % 
12 % 
12 % 
8 % 
8 % 
Table 6.1 
Гйе recovery of lei/Xaemic cells and the percentage of prolif­
erating cells or" given after density centri fugaЬіоп of bone 
marrow sanplee taken before and 60 minutes after Ara-C adminis-
Lration. 
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Patient 
Initials 
L.T. 
O.K. 
P.S. 
M.T. 
C.A. 
O.S. 
J.H. 
s.Ρ! 
* 
H.H. 
J.L* 
А.к! 
Age 
30 
43 
41 
38 
53 
23 
56 
19 
28 
31 
57 
Sex 
M 
Di agnosis 
AML 
AML 
AML 
AML 
AML 
AML 
AMML 
AML 
AMML 
AMML 
AML 
State of 
disease 
Relaose 
First 
First 
First 
First 
First 
First 
First 
Relapse 
Relapse 
First 
Inhibí ti on 
percentage 
95 
90 
86 
81 
79 
78 
73 
69 
65 
50 
33 
Durati on 
first 
course 
14 
10 
14 
10 
14 
14 
10 
14 
14 
10 
10 
Result 
of 
therapy 
CR 
CR 
CR 
CR 
PR 
CR 
PR 
F 
F 
F 
F 
Duration 
second 
course 
10 
10 
6 
10 
14 
6 
Resul t 
of 
therapy 
CR 
CR 
t 
F 
F 
PR 
Table б.II 
The relation between the inhibition of HTdR incorporation 
(inhibition percentage) and the result of Ara-C therapy is 
demonstrated in eleven AML patients. The patients were sub­
divided in acute myeloid leukaemia (AML) and acute myelo-
monoblastic leukaemia (AMML). 
During the first and second course patients in general were 
treated with Ara-C in a dose of 100 mg/m every 12 hours for 
10 or 14 days. 
* These four patients were treated during the second course 
with Ara-C starting on day 3 in combination with Adriamycin 
(day 1) and Vincristine (day 2). One patient died during treatment (i) 
CR is complete remission; PR is partial remission; F is failure. 
(see "methods"). 
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theragy. 
3 
The inhibition of HTdR incorporation found with the Ara-C 
sensitivity test ranged from 33 % - 95 % in eleven AML patients 
(Table 6 . I I ) . Four patients with inhibition percentage above 
80 % came into complete remission after the first course of 
treatment. 
Three patients had an inhibition percentage within the range of 
70 % - 80 %. One of these patients came into complete remission 
and two patients into partial remission after the first course. 
These two patients came into complete remission after a second 
course. 
Four patients with inhibition percentages ranging from 33 % to 
69 % failed on therapy after the first course. In a second course 
these patients were treated with Ara-C in combination with Adria-
mycin and Vincristine. Two patients failed on this second course, 
one patient came into partial remission and one patient died 
during treatment. 
6.4 DISCUSSION 
After intravenous administration of Ara-C the drug is dis-
tributed over the entire body and transported into the cell by 
a carrier mediated diffusion process (Mulder et al., 1 9 7 5 ) . The 
amount of Ara-C in the cell depends on the duration of an 
effective drug level in the blood (Mellet, 1 9 7 2 ) . In the cell, 
the Ara-C molecule is either activated by phosphorylation to 
Ara-CTP (Chu et al., 1965) or inactivated by deamination to 
Ara-U (Camiener, 1 9 6 7 ) . T h u s , the amount of Ara-CTP formed intra-
cellularly will depend on a) the amount of drug transported 
into the cell and b) the relative proportions of drug phospho-
rylated and deaminated. Ara-CTP inhibits DNA synthesis. It is 
3 
assumed that the inhibition of HTdR incorporation reflects the 
amount of Ara-CTP in the cell. 
The test presented in this paper is easy to perform and takes 
about four hours. The relation between this test and the result 
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of therapy was studied in eleven patients. An inhibition 
percentage higher than 70 % was found in seven patients. All 
these patients came into complete remission after one or two 
courses with Ara-C alone. Four patients with an inhibition per-
centage lower than 70 % failed on the first course and were 
treated during a second course with a combination of Ara-C, 
Adriamycin and Vincristine. Of the patients treated in this 
way, only one came into partial remission, one died while 
under treatment and two failed on therapy (table 6.11). 
Although the number of patients is rather small the data suggest 
that the Ara-C sensitivity test may have a predictive value. 
Patients with a high inhibition percentage can be treated success-
fully with Ara-C alone. Apparently patients with a low inhibition 
percentage are rather insensitive to Ara-C and should not be 
treated with this drug alone. The test appears to be of lesser 
value in predicting the response of therapy in patients with 
inhibition percentages of about 60 % to 70 % . 
The predictive value of the test may improve by determining 
3 
the inhibition of HTdR incorporation at other time intervals 
after Ara-C administration. 
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CHAPTER 7 
THE ARA-C SENSITIVITY AS A RESULTANT 
OF PLASMA HALF-LIFE AND INTRACELLULAR 
DEAMINATING ACTIVITY 
ABSTRACT 
3 
The amount of tritiated thymidine ( HTdR) incorporated into 
leukaemic bone marrow cells, obtained from marrow aspirates taken 
before and one hour after administration of Ara-C, is determined 
3 
in the Ara-C sensitivity test. The observed decrease of HTdR 
incorporation is expressed as an іпЬіЪъЬгоп peroentage (I.P.) 
reflecting the responsiveness to the drug, which will depend 
on the plasma half-life and the intracellular deaminating activ-
ity. jo obtain information about the value of the Ara-C sensi-
3 
tnvity test, the inhibition percentage of HTdR incorporation 
was measured simultaneously with the plasma half-life and intra­
cellular deamination of Ara-C in 12 AML patients. 
Complete remission was achieved in seven patients with an inhibi­
tion percentage of more than 70 % and plasma half-life values 
exceeding 13 minutes. Five of these patients who had low deamina­
ting activities came into complete remission after one course 
while the two other patients with high deaminating activities 
needed two courses to achieve complete remission. 
A poor bone marrow response was found in three patients with an 
inhibition percentage below 70 "<. and plasma half-life values less 
than 10 minutes. One of these patients with a low deaminating 
activity came into partial remission after two courses. The other 
two patients with high deaminating activities failed on prolonged 
treatment. Two patients died during therapy. 
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7.1 INTRODUCTION 
As described in chapter 4 we found a relation between the 
plasma half-life of Ara-C and the result of remission inducing 
therapy. Complete remission was attained in patients with an 
average plasma half-life of 15 minutes, while patients with an 
average half-life of 9 minutes showed a poor response to therapy. 
These data suggest that the plasma half-life determines the amount 
of Ara-C taken up by the cells. 
In the cell the drug is activated by phosphorylation to its tri-
phosphate Ara-CTP (Chu et al., 1965) or inactivated by deamination 
to uracil arabi nos i de (Camiener, 1967). Steuart and Burke (1971) 
observed that the deaminating activity in the leukaemic cells 
influences the cytotoxic effect of the drug. The Ara-C sensitivity 
test, described in chapter 6, reflects the net effect of plasma 
half-life, the deaminating activity as well as the phosphorylating 
capacity in the leukaemic cells. 
In this chapter the value of the Ara-C sensitivity test is studied 
in relation to the plasma half-life, the deaminating activity and 
the response to therapy in 12 AML patients. 
7.2 MATERIAL AND METHODS 
Patients 
Twelve AML patients were studied, four males and eight females. 
The mean age was 39 years (ranging from 19 to 5 7 ) . Nine patients 
were first treated and three patients were treated for a relapse. 
The diagnoses were confirmed at the W.H.O. Reference Centre for 
Leukaemias, Villejuif, France and the Leukaemia Working Group in 
the Netherlands. 
Treatment 
All patients were treated with bolus injections of Ara-C in a 
2 
dose of 100 mg/m every 12 hours during the first remission 
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inducing course of treatment. The duration and composition of the 
second course depended on the result of the first course which was 
studied when the bone marrow was repopulated. Complete remission 
was defined as a sta e of normal bone marrow cellularity (less than 
5 % blast cells) and normal peripheral blood values. When a consid-
erable decrease in the leukaemic cells of the bone marrow (blast 
cells between 5 % and 40 %) was found, the result of treatment was 
defined as a partial remission (PR) and treatment was continued 
with Ara-C. When no response in the bone marrow (leukaemic cells 
more than 40 %) was found the result of treatment was defined as 
a failure (F) and a second course of treatment was given with 
Ara-C in combination with Adriamycin and Vincristine. The final 
result of treatment was evaluated after the second course of 
treatment. 
During treatment patients were hospitalized in germ-poor isolation 
units. All patients received supportive treatment with granulo-
cytes and platelets concentrates during the aplastic phase. 
d§If:lif§_9f_Ar§:Ç 
The plasma Ara-C concentrations were determined after an 
2 intravenous bolus injection of 100 mg/m in a bio-assay as 
described in chapter 3. 
Ib§-£!T§:Ç-§§Q§i£ivity_test 
3 
The estimation of the difference in HTdR incorporation in the 
leukaemic bone marrow cells taken before and 60 minutes after an 
intravenous bolus injection of Ara-C is described in chapter 6. 
QEÌ§C5ÌQ§M90_°f-Ìhe_deaminating_actiyitY_in_leukaemic_ce^s 
The ability of the leukaemic cells to deaminate Ara-C was 
determined in a crude extract of these cells. A marrow aspirate, 
taken before administration of Ara-C, was layered on Ficoll Iso-
paque (sg. 1.074 g/ml , 25 C) according to Loos and Roos (1974). 
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After centri fugation (30 min, 1100 χ g, 0 С ) , the cells at the 
interface were suspended in Krebs Ringer Tris solution (pH 7.4) 
to a density of 14 χ 10 cells/ml. The cells were disrupted by 
freezing and thawing (5 t i m e s ) . The crude extract (350 μ!) was 
3 
incubated with 100 nmol Ara-C and 0.06 nmol Η Ara-C (spec. act. 
15 Ci/mmol Radiochemical Centre, Amersham)at 37 С for 60 minutes 
in a total volume of 400 μΐ. The reaction was stopped by adding 
50 ug tetrahydrouridi ne (20 yl) at 0 С together with an excess 
of unlabeled Ara-C and Ara-U. A 10 μΐ aliquot of the reaction 
mixture was spotted on silicagel glass plates (F 254, Merck, 
D a r m s t a d t ) . The plates were developed in water saturated 1-buta-
nol according to Scheit (1967). The Ara-U spots were scraped off 
and suspended in 4 ml distilled water and 6 ml Instagel (Packard) 
and assayed for radioactivity in a liquid scintillation counter 
(LKB 8 1 0 0 0 ) . The deaminating activity is expressed in nmol Ara-C/ 
Q 
hour/10 cells. The enzymatic conversion of Ara-C in Ara-U was 
linear during 60 minutes of incubation. In cases of a high deami­
nating activity the crude extract was diluted. 
7.3 RESULTS 
l!]hibitlï;__of__ idR_inçgrgoration_in_relation_to_glasnia_half3life 
and intracellular deamination 
The Ara-C sensitivity test, the plasma half-life and the intra-
cellular deaminating activity in the leukaenic bone marrow cells 
were determined in 12 AML patients before the start of therapy. 
Fig 7.1 shows the inhibition percentages plotted versus the plasma 
half-life values. The inhibition percentage was high (> 70 %) in 
nine patients with plasma half-life values exceeding 11 minutes. 
Three patients with plasma half-life values of less than 10 minutes 
disclosed rather low inhibition percentages (< 65 % ) . Fig 7.2 
shows the inhibition percentages plotted versus the deaminating 
activities in the leukaemic cells. Although no impressive relation 
was found, the inhibition percentages tended to decrease at 
increased deaminating activities. This relation is partly obscured 
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The relation between the results of the Ara-C sensitivity test 
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12 AML patients. 
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by the i n f l u e n c e o f t h e plasma h a l f - l i f e i n t h e Ara-C s e n s i t i v i t y 
t e s t ( t a b l e 7 . 1 ) . Two out of t h r e e p a t i e n t s who were t r e a t e d f o r 
a r e l a p s e and were r e s i s t a n t t o f u r t h e r t h e r a p y showed very h i g h 
d e a m i n a t i n g a c t i v i t i e s . 
Patient 
Initials 
L.T. 
O.K. 
P.S. 
H.V. 
M.T. 
C.A. 
D.S. 
J.H. 
S.P. 
H.H. 
J.L* 
Α.κ· 
Sex 
F 
F 
M 
M 
F 
F 
F 
M 
F 
F 
F 
M 
Age 
30 
43 
41 
47 
36 
53 
23 
56 
19 
28 
31 
57 
State of 
di sease 
Rel apse 
First 
First 
First 
Fi rst 
First 
First 
First 
First 
Rel apse 
Relapse 
First 
Ara-C t 
first 
course 
(days) 
14 
10 
14 
10 
10 
14 
14 
10 
14 
14 
10 
10 
reatment 
second 
course 
(days) 
10 
10 
10 
14 
6 
PI asma 
half life 
(mm) 
18.9 
15.5 
16.6 
14.7 
13.3 
14.6 
14.3 
18.0 
11.5 
9.5 
8.8 
6.6 
Inhibí ti on 
percentage 
95 
90 
86 
81 
81 
79 
78 
73 
69 
65 
50 
33 
Oeaminase 
activity 
nmol/hr 
108 cells 
18 
48 
233 
293 
126 
324 
342 
574 
247 
880 
485 
209 
Result of 
remission 
ι nduction 
CR. 
CR. 
CR. 
t 
CR. 
CR. 
CR. 
CR. 
+ 
F 
F. 
P.R. 
Table 7.1 
In 12 AML patients the relation between the plasma half-life, 
the deaminating activity, the inhibition percentage of the $ 
HTdR incorporation and the result of therapy is demonstrated. 
Patients were subdivided in acute myeloid leukaemia (AMD and 
acute myelo-monoblastic leukaemia (AMML). 
* These patients were treated with Ara-C starting on day Ζ in 
combination with Adriamyain (day 1) and Vincristine (day 2) 
during the second course of treatment. 
CR is complete remission; PR is partial remission; F is failure 
of therapy. 
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The result of theragy in relation to plasma h a l f - l i f e 2 intracel 
lular d e a m m a t i o n and inhibition of H T d R i ncorgorati on 
The chance of achieving complete remission in acute myeloid 
leukaemia with Ara-C is positively related to the inhibition oer-
centage in the Ara-C sensitivity test (chapter 6) To investigate 
the factors which influence the results of the Ara-C sensitivity 
test, the plasma half-life of Ara-C and the intracellular deamina-
ting activity were measured and weighted against the result of 
therapy. The patients were treated and evaluated as indicated under 
"methods". Two patients died during treatment. Ten patients were 
evaluable (table 7 . 1 ) . 
Complete remission and a high inhibition percentage (I.P. > 70 %) 
was achieved in seven patients. Four out of five patients with a 
g 
relatively low d e a m m a t i n g activity (< 300 nmol/h/10 cells) came 
into complete remission after one course of treatment. Two patients 
о 
with d e a m m a t i n g activities of 324 and 574 nmol/h/10 cells needed 
two courses to achieve complete remission. 
A poor bone marrow response and a low inhibition percentage (I.P. 
< 70 %) was found in three patients. Partial remission was achieved 
in one patient with a relatively low d e a m m a t i n g activity (< 300 
о 
nmol/h/10 cells) and a complete failure of theraoy was found in 
the other two patients who showed very high d e a m m a t i n g activities 
(> 450 n m o l / h / 1 0 8 cells) . 
7 4 DISCUSSION 
It is assumed that the inhibition percentage as determined in 
the Ara-C sensitivity test is related to the amount of Ara-CTP 
formed in the leukaemic cells (Chou et al., 1 9 7 5 ) , which m turn 
depends among other things, on the plasma half-life and the deami-
nating activities in the cell. The inhibition percentage in re­
lation to these two parameters was studied. 
A relation was found between the inhibition percentage and the 
plasma half-life, while no impressive correlation was found 
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between the inhibition percentage and the deaminating activities. 
The inhibition percentages seems to decrease at increasing deamina­
ting activities. These data suggest that the plasma half-life 
largely determines the extent of the inhibition percentage. 
In chapter б a relation was found between the inhibition percent­
age and the result of therapy. Patients with a high inhibition 
percentage (I.P. > 70 %) came into complete remission, while 
patients with a low inhibition percentage (I.P. < 70 %) gene­
rally failed on therapy. 
In this study complete remission associated with a high inhibition 
percentage (I.P. > 70 %) was found in seven patients. Four out of 
five of these patients with low deaminating activities (< 300 
g 
nmol/h/lO cells) came into complete remission after the first 
course of treatment. The other two patients with high deaminating 
о 
activities (> 300 nmol/h/10 cells) needed two courses to achieve 
complete remission. The relatively low inhibition percentages 
in these two patients may be due to the rather high deaminating 
activities requiring a prolonged treatment. 
No complete remission, associated with low inhibition percentages 
(I.P. < 70 %) was found in three patients with plasma half-life 
values below 10 minutes. In one of these patients the deaminating 
p 
activity was low (< 300 nmol/h/10 cells) and partial remission 
was achieved after two courses. After four courses this patient 
came into complete remission. In the two other patients with high 
Q 
deaminating activities (> 450 nmol/h/10 cells) no response to 
therapy was found. 
Despite the small number of patients some preliminary conclusions 
can be made. The plasma half-life is an important parameter for 
the chance to achieve a complete remission. The deaminating activ­
ity in the leukaemic cells is a second factor of importance for 
the result of therapy. The plasma half-life as well as the deami­
nating activity is reflected in the Ara-C sensitivity test. 
In patients with plasma half-life values exceeding 13 minutes, 
the deaminating activity is of minor importance since all these 
patients came into complete remission after one or two courses 
of treatment. In patients with half-life values below 10 minutes 91 
the deaminating activity is of more importance since complete 
remission could be achieved after prolonged treatment in a patient 
with a rather low deaminating activity, while two others with 
high deaminating activities were resistant. 
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SUMMARY 
The cytotoxic drug cytosine arabinoside (Ara-C) is at the 
moment the drug of choice in the treatment of acute myeloid leu-
kaemia (AML). Unfortunately the results of remission inducing 
therapy are still disappointing. At most in 60 percent of the 
patients complete remission is achieved. The failure of treatment 
may be due to individual differences in pharmacokinetics and 
metabolism of the cytotoxic drug. This was studied in a number of 
AML patients as outlined in CHAPTER 1. 
In CHAPTER 2 the present knowledge of the metabolism and phar-
macology of Ara-C is reviewed. Intracellularly the drug is activated 
to its triphosphate (Ara-CTP) or deaminated to uracil arabinoside 
which is non-toxic. Only in the active form the drug inhibits DNA 
synthesis. The inhibition of DNA synthesis should be more pronounced 
at higher levels of Ara-CTP which is the resultant of the duration 
of an effective plasma Ara-C concentration and the net effect of the 
intracellular enzymatic activities. 
To determine the plasma Ara-C concentrations a sensitive bio-
assay was developed as described in CHAPTER 3. With this assay the 
plasma concentrations are measured at different time intervals 
after an intravenous bolus injection. It appears that the plasma 
Ara-C concentration runs down in a biphasic pattern. From these 
data the plasma half-life is calculated according to the mathemat-
ical analysis of a two compartment open model. It appears that 
complete remission was attained in patients with a relatively long 
half-life of Ara-C, while patients with a short plasma half-life 
failed on therapy as described in CHAPTER 4. 
The observed differences in plasma half-life could be due to 
variations in the amount of drug bound to plasma proteins. To 
explore this supposition the protein binding of Ara-C was measured 
in plasma samples and amounted approximately 13 %. From pharmaco-
kinetic studies with other drugs it can be concluded that such a 
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minor protein binding does not affect the plasma half-life of Ara-C. 
As is concluded in CHAPTER 4 the result of treatment in AML 
depends largely on the plasma half-life of Ara-C. The measurement 
of plasma Ara-C concentrations is time consuming and not suitable 
for routine use in clinical situations. To measure the effectivity 
of Ara-C on the leukaemic bone marrow cells a simple sensitivity 
test was developed as described in CHAPTER 6. The test is based on 
3 
the incorporation of tritiated thymidine ( HTdR) in isolated leu-
kaemic bone marrow cells before and one hour after Ara-C a d m i m s -
tration. The observed difference in HTdR incorporation is ex-
pressed as an inhibition percentage. It appeared that patients 
with an inhibition percentage above 70 % came into complete remis-
sion after one or two courses with Ara-C. Patients with an inhibi-
tion percentage below 70 t in general failed on therapy. 
Since the inhibition percentage, as measured in the sensitivity 
test not only depends on plasma half-life but also on the intra-
cellular deaminating activity the relation between these parameters 
and the result of therapy was studied (CHAPTER 7 ) . Although the 
half-life and the result of the Ara-C sensitivity test determine 
to a great extent the response to treatment (CHAPTER 4 and 6 ) , 
a difference in the intensity of treatment,needed to achieve com-
plete remi s si on,s ti 11 exists. Patients with a low deaminating 
activity achieved complete remission after one course while 
patients with a high deaminating activity needed two courses of 
treatment. 
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S T E L L I N G E N 
1 
De dosering van het cytostaticum cytosine arabinoside dat gebruikt 
wordt bij de behandeling van patiënten met acute myeloide leukemie, 
dient te worden aangepast aan de eliminatie snelheid. 
De bevinding dat in muizen de biologische activiteit van het cyto-
staticum cytosine arabinoside sterk toeneemt na toediening van 
tetrahydrouridi ne kan van betekenis zijn voor de behandeling van 
leukemie patiënten, die het cytostaticum snel elimineren. 
Neil, G.L., Moxley, Т.Е., Manak, R.C. (1970) 
Enhancement by tetrahydrouridine of l-ß-D-Ara-
binofuranosylcytosine oral activity in L 1210 
leukaemic mice. Cancer Res. 30, 2166. 
De duur van de cytostatisehe kuren met cytosine arabinoside voor 
het bereiken van complete remissie bij leukemie patiënten dient 
te worden aangepast aan het percentage prol ifererende beenmerg-
cellen. 
De betekenis van 1everscintigrafie voor de stadiëring bij de ziekte 
van Hodgkin is dubieus. 
5 
Met de miltkolonie techniek is door Keizer een beschermend effect 
van sedativa op de stamcellen van net cytostatica behandelende 
proefdieren aangetoond, dat ook zou kunnen worden verklaard door 
een verhoogde affiniteit van de stancellen voor de milt onder in­
vloed van deze sedativa. 
H J Keizer. Proefschrift, 1976 
6 
De toepassing van thrombocyten aggregatie remmers voor de bescher­
ming tegen a r t e n e l e vaatoccl usi es kan mogelijk een klinische be­
tekenis krijgen wanneer de dosering zou worden gerelateerd aan de 
mate waarin de thrombocytenfunktie wordt geremd 
7 
De door lithium verhoogde gevoeligheid van menselijke bloedplaatjes 
voor stoffen die aggregatie induceren blijkt m e t primair te berus­
ten op een verhoogde release van ADP. 
Imandt, J., Genders, T., Wessels, H., Haanen, С. 
(1977). Lithium and human platelets. I Its effect 
on aggregation and release. In the press. 
8 
Bij verschijnselen van pharyngitis dient de palpatie van de schild-
klier uitgevoerd te worden. 
De Pauw, В.E., De Rooy, H.A.M. (1975). De Quer-
v a m ' s subacute thyroiditis. Neth. J. Med 18, 70. 
9 
Gezien de vaak hoge snelheid van tennisballen dient het dragen 
van een vei1 igheidsbri1 voor de netspeler verplicht te worden 
gesteld. 
Nijmegen, 14 januari 1977 H.C. van Prooijen 



